



(86) Date de dépôt PCT/PCT Filing Date: 2003/01/17
(87) Date publication PCT/PCT Publication Date: 2003/07/31
(85) Entrée phase nationale/National Entry: 2004/07/22
(86) N° demande PCT/PCT Application No.: IB 2003/000907
(87) N° publication PCT/PCT Publication No.: 2003/062270
(30) Priorité/Priority: 2002/01/22 (60/351,518) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/12, A01K 67/00, C12N 15/63,
C12N 15/62, C07K 14/435, C07K 16/18

(71) Demandeur/Applicant:
EVROGEN, JSC., RU

(72) Inventeurs/Inventors:
GURSKAYA, NADEJDA, RU;
FRADLOV, ARKADIY, RU;
LUKYANOV, SERGEY, RU;
PUNKOVA, NATALIA, RU

(74) Agent: DEETH WILLIAMS WALL LLP

(54) Titre : NOUVELLES PROTEINES FLUORESCENTES ISSUES DE AEQUOREA COERULSCENS ET LEURS
PROCEDES D'UTILISATION

(54) Title: FLUORESCENT PROTEIN FROM AEQUOREA COERULSCENS AND USES THEREOF

(57) **Abrégé/Abstract:**

The present invention provides nucleic acid compositions encoding a novel colorless GFP-like protein, acGFP, from *Aequorea coerulea* and fluorescent and non-fluorescent mutants and derivatives thereof, as well as peptides and proteins encoded by these nucleic acid compositions. The subject protein and nucleic acid compositions of the present invention are colored and/or fluorescent and/or can be photoactivated, and can be used in a variety of different biological applications, particularly for labeling. Finally, kits for use in such biological applications are provided.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 2003/062270 A3

- (51) International Patent Classification⁷: C12N 15/12, 15/63, C07K 14/435, C12N 15/62, C07K 16/18, A01K 67/00
- (21) International Application Number: PCT/IB2003/000907
- (22) International Filing Date: 17 January 2003 (17.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/351,518 22 January 2002 (22.01.2002) US
- (71) Applicant (for all designated States except US): **EVROGEN, JSC** [RU/US]; 16/10 Miklukho-Maklaya Street, Moscow, AL 77777 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GURSKAYA, Nadejda** [RU/RU]; Moscow (RU). **FRADLOV, Arkadiy** [RU/RU]; Moscow (RU). **LUKYANOV, Sergey** [RU/RU]; Moscow (RU). **PUNKOVA, Natalia** [RU/RU]; Moscow (RU).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— with amended claims
- (88) Date of publication of the international search report: 27 November 2003
- Date of publication of the amended claims: 1 April 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FLUORESCENT PROTEIN FROM AEQUOREA COERULSCENS AND USES THEROF

(57) Abstract: The present invention provides nucleic acid compositions encoding a novel colorless GFP-like protein, acGFP, from *Aequorea coerulea* and fluorescent and non-fluorescent mutants and derivatives thereof, as well as peptides and proteins encoded by these nucleic acid compositions. The subject protein and nucleic acid compositions of the present invention are colored and/or fluorescent and/or can be photoactivated, and can be used in a variety of different biological applications, particularly for labeling. Finally, kits for use in such biological applications are provided.

WO 2003/062270 A3

**NOVEL FLUORESCENT PROTEINS FROM *AEQUOREA COERULSCENS* AND
METHODS FOR USING SAME**

INVENTORS:

**Nadejda Gurskaya
Arkadiy Fradlov
Sergey Lukyanov
Natalia Punkova**

[0001] FIELD OF THE INVENTION

[0002] This invention relates to fluorescent proteins.

[0003] BACKGROUND OF THE INVENTION

[0004] Labeling is a tool for marking a protein, cell, or organism of interest and plays a prominent role in many biochemical, molecular biological and medical diagnostic applications. A variety of different labels have been developed and used in the art, including radiolabels, chromolabels, fluorescent labels, chemiluminescent labels, and the like, with varying properties and optimal uses. However, there is continued interest in the development of new labels. Of particular interest is the development of new protein labels, including fluorescent protein labels.

[0005] RELEVANT LITERATURE

[0006] U.S. Patents of interest include: 6,066,476; 6,020,192; 5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445; 5,874,304; and 5,491,084. International Patent Publications of interest include: WO 00/46233; WO 99/49019; and DE 197 18 640 A. Also of interest are: Anderluh et al., Biochemical and Biophysical Research Communications (1996) 220:437-442; Dove et al., Biological Bulletin (1995) 189:288-297; Fradkov et al., FEBS Lett. (2000) 479(3):127-30; Gurskaya et al., FEBS Lett., (2001) 507(1):16-20; Gurskaya et al., BMC Biochem. (2001) 2:6; Lukyanov, K., et al. (2000) J. Biol. Chemistry 275(34):25879-25882; Macek et al., Eur. J. Biochem. (1995) 234:329-335; Martynov et al., J. Biol. Chem. (2001) 276:21012-6; Matz, M.V., et al. (1999) Nature Biotechnol., 17:969-973; Terskikh et al., Science (2000) 290:1585-8; Tsien, Annual Rev. of Biochemistry (1998) 67:509-544; Tsien, Nat. Biotech. (1999) 17:956-957; Ward et al., J. Biol.

Chem. (1979) 254:781-788; Wiedermann et al., Jahrestagung der Deutschen Gesellschaft für Tropenökologie-gto. Ulm. 17-19.02.1999. Poster P-4.20; Yarbrough et al., Proceedings of the National Academy of Sciences (2001) 98:462-7.

[0007] **SUMMARY OF THE INVENTION**

[0008] The present invention provides nucleic acid compositions encoding a unique colorless protein from *Aequorea coerulea* and fluorescent and non-fluorescent mutants thereof, as well as the proteins and peptides encoded by the nucleic acids. The proteins of the present invention are proteins that are colored and/or fluorescent and/or can be photoactivated, where this optical feature arises from the interaction of two or more amino acid residues of the protein. Also of interest are proteins that are substantially similar to, or derivatives or mutants of, the above-referenced specific proteins including fusion proteins incorporating peptides of the present invention, as well as antibodies to these proteins. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, the present invention provides kits for use in labeling applications.

[0009] **DESCRIPTION OF THE FIGURES**

[0010] Figure 1 is the amino acid sequence and the nucleic acid sequence encoding the wild type GFP-like protein from *Aequorea coerulea*, herein referred to as acGFP.

[0011] Figure 2 is the comparison of *Aequorea victoria* GFP and *Aequorea coerulea* acGFP amino acid sequences.

[0012] Figure 3 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, Z1.

[0013] Figure 4 is the excitation-emission spectra for mutant Z1.

[0014] Figure 5 is the amino acid sequence and the nucleic acid sequence the acGFP sequence mutant, Z2.

[0015] Figure 6 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, G1.

[0016] Figure 7 is the amino acid sequence and the nucleic acid encoding the acGFP mutant, G2.

[0017] Figure 8 is the excitation-emission spectra for mutant G2.

[0018] Figure 9 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, G22.

[0019] Figure 10 is the excitation-emission spectra for mutant G22.

[0020] Figure 11 is a protein gel-electrophoresis analysis of wildtype acGFP and acGFP mutants.

[0021] Figure 12 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, G22-G222E.

[0022] Figure 13 is the absorption and excitation-emission spectra for mutant G22-G222E.

[0023] Figure 14 provides the spectra for UV-induced photoconversion of G22-G222E.

[0024] Figure 15 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, G22-G222E/Y220L.

[0025] Figure 16 is the excitation-emission spectra for mutant G22-G222E/Y220L.

[0026] Figure 17 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, 220-II-5.

[0027] Figure 18 provides spectral properties of mutant 220-II-5.

[0028] Figure 19 is the amino acid sequence and the nucleic acid sequence encoding the acGFP mutant, CFP-rand3.

[0029] Figure 20 is the excitation-emission spectra for mutant CFP-rand3.

[0030] Figure 21 is the amino acid sequence and the nucleic acid sequence encoding acGFP mutant, CFP-3.

[0031] Figure 22 provides spectral properties of mutant CFP-3.

[0032] Figure 23 is the amino acid and nucleic acid sequences for a humanized version of mutant G22.

[0033] Figure 24 shows microphotographs of mammalian cells expressing mutant G22.

[0034] Figure 25 shows the photoactivation of mutant 220-11-5 in *E. coli* colonies.

[0035] **DESCRIPTION OF THE INVENTION**

[0036] The subject invention provides a nucleic acid, wherein the nucleic acid encodes a fluorescent protein, acGFP, or a mutant or derivative thereof. In certain embodiments, the nucleic acid is isolated, or has been engineered or is present in an environment other than its natural environment. In certain embodiments, the nucleic acid has a sequence of residues that is substantially the same as, or identical to, a nucleotide sequence of at least 10 residues in length from SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21, or 23.

[0037] In certain embodiments, the nucleic acid of the present invention has a sequence similarity of at least about 60% with a sequence of SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21, or 23, and is at least 10 residues in length. In certain embodiments, the nucleic acid of the present invention encodes a protein that has an amino acid sequence selected from the group consisting of SEQ ID NO: 02, 04, 06, 08, 10, 12, 14, 16, 18, 20, 22, or 24, encoding a mutant or derivative protein of a *Aequorea coerulescens* fluorescent protein.

[0038] Also provided are fragments of the nucleic acids of the present invention. Additionally, nucleic acids or mimetics thereof that hybridize under stringent conditions to the nucleic acids of the present invention are provided. Also provided

are constructs comprising a vector and a nucleic acid of the present invention. In addition, the present invention provides expression cassettes that include: a transcriptional initiation region functional in a expression host, a nucleic acid of the present invention, and a transcriptional termination region functional in the expression cassette as part of an extrachromosomal element or integrated into the genome of the cell as a result of introduction of said expression cassette into the cell.

[0039] Also provided are methods of producing a chromogenic and/or fluorescent protein including growing a cell of the present invention, expressing the protein in the cell, and isolating the protein substantially free of other proteins.

[0040] In addition, proteins or fragments or peptides encoded by a nucleic acid of the present invention are provided, as are antibodies that bind specifically to the proteins or peptides of the present invention.

[0041] Additionally, transgenic cells (or their progeny) that include a nucleic acid of the present invention are provided, as are transgenic organisms that include a nucleic acid of the present invention.

[0042] Also provided are methods that employ a chromo- or fluorescent protein of the present invention, or that employ a nucleic acid encoding a chromogenic or fluorescent protein of the present invention.

[0043] Additionally, kits that include a nucleic acid or protein according to the subject invention and instructions of use therefor, are provided.

[0044] In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the sill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, Volumes I and II (D.N. Glover, ed. 1985); Oligonucleotide Synthesis (M.J. Gait, ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins, eds. (1984)); Animal Cell Culture (R.I. Freshney, ed. (1986)); Immobilized Cells and Enzymes (IRL Press (1986)); and B. Perbal, A Practical Guide to Molecular Cloning (1984).

[0045] A “vector” is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached.

[0046] A “DNA molecule” refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single-stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, “DNA molecule” includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.

[0047] A DNA “coding sequence” is a DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and synthetic DNA sequences. A polyadenylation signal and transcription termination sequence may be located 3' of the coding sequence.

[0048] As used herein, the term “hybridization” refers to the process of association of two nucleic acid strands to form an antiparallel duplex stabilized by means of hydrogen bonding between residues of the opposite nucleic acid strands.

[0049] The term “oligonucleotide” refers to a short (under 100 bases in length) nucleic acid molecule.

[0050] “DNA regulatory sequences”, as used herein, are transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for and/or regulate expression of a coding sequence in a host cell.

[0051] A “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a coding sequence. For example, the promoter sequence may be bounded at its 3' terminus by the transcription initiation site and extend upstream (5' direction) to include the minimum

number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence may be found a transcription initiation site, as well as protein binding domains responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Various promoters, including inducible promoters, may be used to drive the various vectors of the present invention.

[0052] As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

[0053] A cell has been "transformed" or "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a host cell chromosome or is maintained extra-chromosomally so that the transforming DNA inherited by daughter cells during cell replication. Such a stably transformed eukaryotic cell is able to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone or a cell that is capable of stable growth *in vitro* for many generations.

[0054] A "heterologous" region of a DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature; for example, when the heterologous region encodes a mammalian genomic DNA in the genome of a non-mammalian organism. In another example, heterologous DNA includes coding sequences in a construct where portions of genes from two different sources have been brought together so as to produce a fusion protein product.

[0055] As used herein, the term "reporter gene" refers to a coding sequence attached to heterologous promoter or enhancer elements and whose product may

be assayed easily and quantifiably when the construct is introduced into tissues or cells.

[0056] The amino acids described herein are preferred to be in the "L" isomeric form. The amino acid sequences are given in one-letter code (A: alanine; C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; G: glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M: methionine; N: asparagine; P: proline; Q: glutamine; R: arginine; S: serine; T: threonine; V: valine; W: tryptophan; Y: tyrosine; X: any residue). NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. Standard polypeptide nomenclature, see J. Biol. Chem., 243, 3552-59 (1969), is used.

[0057] The term "immunologically active" defines the capability of the natural, recombinant or synthetic chromogenic or fluorescent protein, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. As used herein, "antigenic amino acid sequence" means an amino acid sequence that, either alone or in association with a carrier molecule, can elicit an antibody response in a mammal. The term "specific binding," in the context of antibody binding to an antigen, is a term well understood in the art and refers to binding of an antibody to the antigen to which the antibody was raised, but not other, unrelated antigens.

[0058] As used herein the term "isolated" is meant to describe a polynucleotide, a polypeptide, an antibody, or a host cell that is in an environment different from that in which the polynucleotide, the polypeptide, and antibody, or the host cell naturally occurs.

[0059] Bioluminescence is emission of light by living organisms that is visible in the dark. (See, e.g., Harvey, Bioluminescence, New York: Academic Press (1952); Hastings, "Bioluminescence" in: Cell Physiology (ed. by Speralakis), New York Academic Press pp. 651-81 (1995); Wilson and Hastings, "Bioluminescence", Annu. Rev. Cell. Dev. Biol. 14, pp.197-230 (1998)). Bioluminescence does not include so-called ultra-weak light emission, that can be detected in virtually all living structures using sensitive luminometric equipment (Murphy and Sies, "Visible-range low-level

chemiluminescence in biological systems”, Meth. Enzymol. 186, pp. 595-610 (1990); Radotic, et al., “Spontaneous ultra-weak bioluminescence in plants: origin, mechanisms and properties”, Gen. Physiol. Biophys. 17, pp. 289-308 (1998)), nor does bioluminescence emanate from weak light emission which most probably does not play an ecological role, such as the glowing of a bamboo growth cone (Totsune, et al., “Chemiluminescence from bamboo shoot cut”, Biochem. Biophys. Res. Comm. 194, pp. 1025-1029 (1993)), or emission of light during the fertilization of animal eggs (Klebanoff, et al., “Metabolic similarities between fertilization and phagocytosis”, J. Exp. Med. 149, pp. 938-53 (1979); Schomer and Epel, “Redox changes during fertilization and maturation of marine invertebrate eggs”, Dev. Biol. 2003, pp. 1-11 (1998)).

[0060] As used herein, the term “GFP-like proteins” is meant to describe proteins similar to the green fluorescent protein (GFP) from *Aequorea victoria*.

[0061] Nucleic acid compositions encoding a colorless GFP-like protein, acGFP, from *Aequorea coerulea*, and fluorescent and non-fluorescent derivatives or mutants thereof, as well as proteins and peptides encoded by these nucleic acid composites are provided. The proteins of interest are proteins that are colored and/or fluorescent and/or can be photoactivated, where the color, fluorescent, or photoactivation feature arises from the interaction of two or more amino acid residues of the protein. Also of interest are proteins that are substantially similar to, or derivatives or mutants of, the above-referenced specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and peptides. In addition, transgenic cells and organisms are provided. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly protein labeling applications. Finally, kits for use in such methods and applications are provided.

[0062] Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the invention. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting.

[0063] In this specification, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the invention.

[0064] In describing the present invention, nucleic acid compositions will be described first, followed by a discussion of protein compositions, antibody compositions and transgenic cells and organisms. Next a review of exemplary methods in which the proteins of the present invention find use is provided.

[0065] Nucleic Acid Compositions

[0066] As summarized above, the present invention provides nucleic acid compositions encoding a colorless protein, acGFP, from *Aequorea coerulea*, or fluorescent and non-fluorescent mutants or derivatives of acGFP, as well as fragments and homologs of the nucleic acid compositions. The phrase “fluorescent protein” means a protein that is fluorescent; e.g., it may exhibit low, medium or intense fluorescence upon irradiation with light of the appropriate excitation wavelength. The proteins of the present invention are those in which the fluorescent characteristic is one that arises from the interaction of two or more amino acid residues of the protein, and not from a single amino acid residue. As such, the fluorescent proteins of the present invention do not include proteins that exhibit fluorescence only from residues that act by themselves as intrinsic fluorophores, i.e., tryptophan, tyrosine and phenylalanine. The fluorescent proteins of the subject invention thus are fluorescent proteins whose fluorescence arises from some structure in the protein other than the above-specified single amino acid residues; e.g., it arises from an interaction of two or more amino acid residues.

[0067] One nucleic acid composition of the present invention is a composition comprising a sequence of DNA having an open reading frame that encodes a polypeptide of the subject invention; i.e., a fluoroprotein gene. Such a nucleic acid composition is capable, under appropriate conditions, of being expressed as a fluoroprotein. Also encompassed in the term nucleic acid composition are nucleic acids that are homologous to, substantially similar to, identical to, or mimetics of the nucleic acids of the present invention. The subject nucleic acids are present in an environment other than their natural environment; e.g., they are isolated, present in enriched amounts, or are present or expressed *in vitro* or in a cell or organism other than their naturally occurring environment.

[0068] In another embodiment of the present invention, the nucleic acids may be encoded by SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21 or 23, or are nucleic acids derived from, or are homologs of such nucleic acids.

[0069] In addition to the above-described specific nucleic acid compositions, also of interest are homologs of the above sequences. With respect to homologs of the subject nucleic acids, the source of homologous genes may be any species of plant or animal or the sequence may be wholly or partially synthetic including sequences incorporating nucleic acid mimetics. In certain embodiments, sequence similarity between homologs is at least about 40%, and maybe 50%, 60%, 70% or higher, including 75%, 80%, 85%, 90% and 95% or higher. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 nucleotides long, more usually at least about 30 nucleotides long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul et al., J. Mol. Biol., 215, pp. 403-10 (1990) (for example, using default settings, i.e., parameters $w=4$ and $T=17$).

[0070] Homologs are identified by any of a number of methods. A fragment of a cDNA of the present invention may be used as a hybridization probe against a cDNA library from a target organism of interest, where low stringency conditions are used. The probe may be a large fragment, or one or more short degenerate primers. Nucleic acids having sequence similarity are detected by hybridization

under low stringency conditions, for example, at 50°C and 6xSSC (0.9 M sodium chloride/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1xSSC (0.15 M sodium chloride/.015 M sodium citrate). Sequence identity may be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1xSSC (15 mM sodium chloride/1.5 mM sodium citrate). Nucleic acids having a region of substantial identity to the provided sequences, e.g., allelic variants, genetically-altered versions of the gene, etc., bind to the provided sequences under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes.

[0071] Or particular interest in certain embodiments of the present invention are nucleic acids of substantially the same length as the nucleic acids identified as SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21, or 23, where "substantially the same length" means that any difference in length does not exceed about 20%, usually does not exceed about 10% and more usually does not exceed about 5%. In preferred embodiments nucleotides of substantially the same length will have a sequence identity to SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21 or 23, of at least about 90% (e.g., at least about 92%, 93%, 94%), usually at least about 95%, 96%, 97% or 98% or even about 99% over the entire length of the nucleic acid. "Substantially similar" means that sequence identity will generally be at least about 60%, usually at least about 75% and often at least about 80, 85, 90 (e.g., 92%, 93%, 94%), or even 95%, e.g., 96%, 98%, 98%, 99%, 99.5% or higher.

[0072] In addition, the present invention includes nucleic acids that encode the proteins encoded by the previously-described nucleic acids, but differ in sequence from the previously-described nucleic acids due to the degeneracy of the genetic code.

[0073] Also provided are nucleic acids that hybridize to the above-described nucleic acids under stringent conditions (i.e., complements of the previously-described nucleic acids). An example of stringent hybridization conditions is hybridization at 50°C or higher and 0.1xSSC (15 mM sodium chloride/1.5 mM sodium citrate). Another example of stringent hybridization conditions is overnight incubation at 42°C in a solution of 50% formamide, 5xSSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5 x Denhardt's solution, 10%

destran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1xSSC at about 65°C. Stringent hybridization conditions are hybridization conditions that are at least 80% as stringent as the above-representative conditions. Other stringent hybridization conditions are known in the art and may also be employed to identify nucleic acids of this particular embodiment of the invention.

[0074] Nucleic acids encoding mutants or derivatives of the proteins of the invention also are provided. Mutant nucleic acids can be generated by random mutagenesis or targeted mutagenesis, using techniques well known in the art. Mutations of interest include deletions, additions and substitutions. In some embodiments, fluorescent proteins encoded by nucleic acids encoding homologs or mutants have the same fluorescent properties as the wild type fluorescent protein. In other embodiments, homolog or mutant nucleic acids encode fluorescent proteins with altered spectral properties, as described in more detail for mutant acGFP proteins herein.

[0075] Nucleic acids of the subject invention may be cDNA or genomic DNA or a fragment thereof. In certain embodiments, the nucleic acids of the subject invention include one or more of the open reading frames encoding specific fluorescent proteins and polypeptides, and introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, including sequences up to about 20 kb beyond the coding region, but possibly further, in either direction. The subject nucleic acids may be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome, as described in greater detail below.

[0076] The term "cDNA" as used herein is intended to include nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 5' and 3' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding the protein.

[0077] A genomic sequence of interest may comprise the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. The genomic sequence of interest further may include 5' and 3' un-translated regions found in the mature mRNA, as well as specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kb or smaller; and substantially free of flanking chromosomal sequence. Genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, may contain sequences required for proper tissue- and stage-specific expression.

[0078] The nucleic acid compositions of the subject invention may encode all or a part of the subject proteins. Double- or single-stranded fragments may be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. For the most part, DNA fragments will be at least about 15 nucleotides in length, usually at least about 18 nucleotides in length or about 25 nucleotides in length, and may be at least about 50 nucleotides in length. In some embodiments, the subject nucleotide acid molecules may be about 100, about 200, about 300, about 400, about 500, about 600, about 700 nucleotides or greater in length. The subject nucleic acids may encode fragments of the subject proteins or the full-length proteins; e.g., the subject nucleic acids may encode polypeptides of about 25 amino acids, about 50, about 75, about 100, about 125, about 150, about 200 amino acids up to the full length protein.

[0079] The subject nucleic acids may be isolated and obtained in substantial purity, generally as other than as an intact chromosome. Usually, the DNA will be obtained substantially free of nucleic acid sequences that do not include a nucleic acid of the subject invention or a fragment thereof. Substantial purity means that the nucleic acids are at least about 50% pure, usually at least about 90% pure and are typically "recombinant", i.e., flanked by one or more nucleotides with which it is

not normally associated on a naturally-occurring chromosome in its natural host organism.

[0080] The polynucleotides of the present invention, e.g., polynucleotides having the sequence of SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21 or 23, the corresponding cDNAs, full-length genes and constructs can be generated synthetically by a number of different protocols known to those of skill in the art. Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), and under regulations described in, e.g., United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research.

[0081] Also provided are nucleic acids that encode fusion proteins of the subject protein or peptides of the present invention, or fragments thereof, fused to a second peptide or protein. The second protein may be, for example, a degradation sequence, a signal peptide, or any protein of interest. Fusion proteins may comprise for example, an acGFP or mutant acGFP polypeptide and a second polypeptide ("the fusion partner") fused in-frame at the N-terminus and/or C-terminus of the acGFP polypeptide. Fusion partners include, but are not limited to, polypeptides that can bind antibodies specific to the fusion partner (e.g., epitope tags), antibodies or binding fragments thereof, polypeptides that provide a catalytic function or induce a cellular response, ligands or receptors or mimetics thereof, and the like. In such fusion proteins, the fusion partner is generally not naturally associated with the acGFP portion of the fusion protein, and is typically not an *Aequorea coerulea* protein or derivative/fragment thereof; i.e., it is not found in *Aequorea* species.

[0082] Also provided are vector and other nucleic acid constructs comprising the subject nucleic acids, where such constructs may be used for a number of applications, including propagation, protein production, etc. Viral and non-viral vectors may be prepared and used, including plasmids. The choice of vector will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in

culture. Still other vectors are suitable for transfer and expression in cells in a whole animal. The choice of appropriate vector is well within the skill of the art, and many such vectors are available commercially. To prepare the constructs, the partial or full-length polynucleotide is inserted into a vector typically by means of DNA ligase attachment to a cleaved restriction enzyme site in the vector. Alternatively, the desired nucleotide sequence can be inserted by homologous recombination *in vivo*, typically by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence. Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction using primers comprising both the region of homology and a portion of the desired nucleotide sequence, for example.

[0083] Also provided are expression cassettes or systems that find use in, among other applications, the synthesis of the subject chromogenic or fluorescent proteins or fusion proteins thereof. For expression, the gene product encoded by a polynucleotide of the invention is expressed in any convenient expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Such vectors and host cells are described in U.S. Patent No. 5,654,173. In the expression vector, a subject polynucleotide -- e.g., as set forth in SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21 or 23 -- is linked to a regulatory sequence as appropriate to obtain the desired expression properties. These regulatory sequences can include promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequences using the techniques described above for linkage to vectors. Any techniques known in the art can be used. In other words, the expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. These control regions may be native to the subject species from which the subject nucleic acid is obtained, or may be derived from exogenous sources.

[0084] Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding heterologous proteins. A selectable marker operative in the expression host may be present. Expression vectors may be used for, among other things, the production of fusion proteins, as described above.

[0085] Expression cassettes may be prepared comprising a transcription initiation region, the gene or fragment thereof, and a transcriptional termination region. Of particular interest is the use of sequences that allow for the expression of functional epitopes or domains, usually at least about 8 amino acids in length, more usually at least about 15 amino acids in length, to about 25 amino acids, and up to the complete open reading frame of the gene. After introduction of the DNA, the cells containing the construct may be selected by means of a selectable marker, the cells expanded, then used for expression.

[0086] The above-described expression systems may be employed with prokaryotes or eukaryotes in accordance with conventional methods, depending upon the purpose for expression. For large-scale production of the protein, a unicellular organism, such as *E. coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, e.g., COS 7 cells, HEK 293, CHO, *Xenopus* oocytes, etc., may be used as the expression host cells. In some situations, it is desirable to express the gene in eukaryotic cells, where the expressed protein will benefit from native folding and post-translational modifications. Small peptides also can be synthesized in the laboratory. Polypeptides that are subsets of the complete protein sequence may be used to identify and investigate parts of the protein important for function.

[0087] Specific expression systems of interest include bacterial-, yeast-, insect cell- and mammalian cell-derived expression systems. References drawn to representative systems from each of these categories are provided below.

[0088] Expression systems in bacteria include those described in Chang et al., Nature 275:615 (1978); Goeddel et al., Nature 281:544 (1979); Goeddel et al., Nucleic Acids Res. 8:4057 (1980); EP 0 036,776; U.S. Patent No. 4,551,433;

DeBoer et al., Proc. Natl. Acad. Sci. (USA) 80:21-25 (1983); and Siebenlist et al., Cell 20:269 (1980).

[0089] Expression systems in yeast include those described in Hinnen et al., Proc. Natl. Acad. Sci. (USA) 75:1929 (1978); Ito et al., J. Bacteriol. 153:163 (1983); Kurtz et al., Mol. Cell Biol. 6:142 (1986); Kunze et al., J. Basic Microbiol. 25:141 (1985); Gleeson et al., J. Gen. Microbiol. 132:3459 (1986); Roggenkamp et al., Mol. Gen. Genet. 202:302; (1986); Das et al., J. Bacteriol. 158:1165 (1984); De Louvencourt et al., J. Bacteriol. 154:737 (1983); Van den Berg et al., Bio/Technology 8:135 (1990); Kunze et al., J. Basic Microbiol. 25:141 (1985); Cregg et al., Mol. Cell. Biol. 5:3376 (1985); U.S. Patent Nos. 4,837,148 and 4,929,555; Beach and Nurse, Nature 300:706 (1981); Davidow et al., Curr. Genet. 10:380 (1985); Gaillardin et al., Curr. Genet. 10:49 (1985); Ballance et al., Biochem. Biophys. Res. Commun. 112:284-289 (1983); Tilburn et al., Gene 26:205-221 (1983); Yelton et al., Proc. Natl. Acad. Sci. (81:1470-1474 (1984); Kelly and Hynes, EMBO J. 4:475479 (1985); EP 0 244, 234: and WO 91/00357.

[0090] Expression of heterologous genes in insects is accomplished as described in U.S. Patent No. 4,745,051; Friesen et al., "The Regulation of Baculovirus Gene Expression", in: The Molecular Biology of Baculoviruses (W. Doerfler, ed.) (1986); EP 0 127,839; EP 0 155,476; and Vlak et al., J. Gen. Virol. 69:765-776 (1988); Miller et al., Ann. Rev. Microbiol. 42:177 (1988); Carbonell et al., Gene 73:409 (1988); Maeda et al., Nature 315:592-594 (1985); Labacq-Verheyden et al., Mol. Cell. Biol. 8:3129 (1988); Smith et al., Proc. Natl. Acad. Sci. 82:8844 (1985); Miyajima et al., Gene 58:273 (1987); and Martin et al., DNA 7:99 (1988). Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow et al., Bio/Technology 6:47-55 (1988); Miller et al., Genetic Engineering 8:277-279 (1986); and Maeda et al., Nature 315:592-594 (1985).

[0091] Mammalian expression is accomplished as described in Dijkema et al., EMBO J. 4:761 (1985), Gorman et al., Proc. Natl. Acad. Sci. (USA) 79:6777 (1982); Boshart et al., Cell 41:521 (1985); and U.S. Patent No. 4,399,216. Other features of mammalian expression are facilitated as described in Hamm and Wallace, Meth. Enz. 58:44 (1979); Barnes and Sata, Anal. Biochem. 102:255 (1980); U.S. Patent

Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; WO 90/103430; WO 87/00195, and U.S. RE 30,985.

[0092] When any of the above-referenced host cells, or other appropriate host cells or organisms are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide is within the scope of the invention as a product of the host cell or organism. The product may be recovered by an appropriate means known in the art.

[0093] Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence inserted into the genome of the cell at location sufficient to at least enhance expression of the gene in the cell. The regulatory sequence may be designed to integrate into the genome via homologous recombination, as disclosed in U.S. Patent Nos. 5,641,670 and 5,733,761, the disclosures of which are herein incorporated by reference, or may be designed to integrate into the genome via non-homologous recombination, as described in WO 99/15650, the disclosure of which also is herein incorporated by reference. As such, also encompassed in the present invention is the production of proteins without manipulation of the encoding nucleic acid itself, but instead through integration of a regulatory sequence into the genome of cell that already includes a gene encoding the desired protein.

[0094] Also of interest are promoter sequences of the genomic sequences of the present invention, where the sequence of the 5' flanking region may be utilized for promoter elements, including enhancer binding sites, that, for example, provide for regulation of expression in cells/tissues where the subject proteins gene are expressed.

[0095] Also provided are small DNA fragments of the subject nucleic acids, that are useful as primers for PCR, hybridization screening probes, etc. Larger DNA fragments are useful for production of the encoded polypeptide, as described previously. However, for use in geometric amplification reactions, such as geometric PCR, a pair of small DNA fragments, i.e., primers, will be used. The

exact composition of the primer sequences is not critical to the invention, but for most applications, the primers will hybridize to the subject sequence under stringent conditions, as is known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nucleotides, preferably at least about 100 nucleotides. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA and will prime toward each other.

[0096] The nucleic acid compositions of the present invention also may be used to identify expression of a gene in a biological specimen. The manner in which one probes cells for the presence of particular nucleotide sequences, such as genomic DNA or RNA, is well established in the art. Briefly, DNA or mRNA is isolated from a cell sample. The mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences. Alternatively, the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, e.g., nitrocellulose, nylon, etc., and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ* hybridizations, and hybridization to DNA probes arrayed on a solid chip may also be used. Detection of mRNA hybridizing to the subject sequence is indicative of gene expression in the sample.

[0097] The subject nucleic acids, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength or to vary the sequence of the encoded protein or properties of the encoded protein, including the fluorescent properties of the encoded protein. The DNA sequence or protein product of such a mutation will be substantially similar to SEQ ID NOS. 1-24 provided herein. The sequence changes of these sequences may be substitutions, insertions, deletions, or a combination thereof. Deletions may further include large changes, such as deletions of a domain or exon, e.g., of stretches of 10, 20, 50, 75, 100, 150 or more amino acid residues. Techniques for *in vitro* mutagenesis may be found in Gustin et al., Biotechniques 14:22 (1993); Barany, Gene 37:111-23 (1985); and Colicelli et al., Mol. Gen. Genet.

199:537-9 (1985). Methods for site-specific mutagenesis can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, CSH Press, pp. 15.3-15.108 (1989). Such mutated nucleic acid derivatives may be used to study structure-function relationships of a particular chromogenic fluorescent protein, or to alter properties of the protein that affect its function or regulation.

[0098] Also of interest are humanized versions of the subject nucleic acids such as the hG22 mutant of acGFP described herein. As used herein, the term "humanized" refers to changes made to the nucleic acid sequence to optimize the codons for expression of the protein in human cells (Yang et al., Nucleic Acids Research 24:4592-93 (1996)). See also U.S. Patent No. 5,795,737 which describes humanization of proteins, the disclosure of which is herein incorporated by reference.

[0099] Peptide Compositions

[00100] The subject invention provides fluorescent protein acGFP and derivatives thereof, as well as related polypeptide fragments. As used herein, the term fluorescent protein refers to any protein that fluoresces when irradiated with light, e.g., white light or light of a specific wavelength (or a narrow band of wavelengths such as an excitation wavelength). The term polypeptide as used herein refers to both full-length proteins, as well as portions or fragments of proteins. Also included in this term are variations of a naturally occurring protein, where such variations are homologous or substantially similar to the naturally occurring protein, and mutants of the naturally occurring proteins, as described in greater detail below. The subject polypeptides are present in environments other than their natural environment.

[00101] In many embodiments, the subject proteins have an absorbance maximum ranging from about 300 nm to 700 nm, usually from about 350 nm to 550 nm and more usually from about 400 to 500 nm, and often from about 450 to 490 nm, e.g., 470 to 490 nm while the emission spectra of the subject proteins typically ranges from about 400 nm to 700 nm, usually from about 450 nm to 650 nm and more usually from about 500 to 600 nm while in many embodiments the emission spectra ranges from about 500 to 550 nm, e.g., 500 to 525 nm, or 500 to 510 nm. The subject proteins generally have a maximum extinction coefficient that ranges

from about 25,000 to 150,000 and usually from about 45,000 to 120,000, e.g., 50,000 to 100,000. The subject proteins typically range in length from about 150 to 300 amino acids and usually from about 200 to 300 amino acid residues, and generally have a molecular weight ranging from about 15 to 35 kDa, usually from about 17.5 to 32.5 kDa.

[00102] In certain embodiments, the subject proteins are bright, where "bright" is meant that the chromoproteins and their fluorescent derivatives can be detected by common methods (e.g., visual screening, spectrophotometry, spectrofluorometry, fluorescent microscopy, by FACS instrumentation, etc.). Fluorescence brightness of a particular fluorescent protein is determined by its quantum yield multiplied by maximal extinction coefficient. Brightness of a chromoprotein may be expressed by its maximal extinction coefficient.

[00103] In certain embodiments, the subject proteins fold rapidly following expression in the host cell. "Rapidly folding" means that the proteins achieve the tertiary structure that gives rise to their chromogenic or fluorescent quality in a short period of time. In these embodiments, the proteins fold in a period of time that generally does not exceed about 3 days, usually does not exceed about 2 days and more usually does not exceed about 1 day.

[00104] Specific proteins of interest include the wild type acGFP fluorescent protein and mutants thereof, as provided, for example, in SEQ ID NO: 02, 04, 06, 08, 10, 12, 14, 16, 18, 20, 22, or 24 coding for acGFP, Z1, Z2, G1, G2, G22, G22-G22E, G22-G22E/Y220L, 220-11-5, CFP-rand3 and CFP-3 and humanized G22.

[00105] Homologs of proteins (or fragments thereof) that vary in sequence from the above-provided specific amino acid sequences, i.e., SEQ ID NO: 02, 04, 06, 08, 10, 12, 14, 16, 18, 20, 22, or 24, are also provided. "Homolog" means a protein having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid sequence identity to amino acid sequences SEQ ID NO: 02, 04, 06, 08, 10, 12, 14, 16, 18, 20, 22, or 24, as determined using MegAlign, DNASTAR clustal algorithm as described in D.G. Higgins and P.M. Sharp, "Fast and Sensitive multiple Sequence Alignments on a Microcomputer," CABIOS, 5 pp. 151-3 (1989) (using parameters ktuple 1, gap penalty 3, window 5 and diagonals saved 5). In

many embodiments, homologs of interest have much higher sequence identity e.g., 65%, 70%, 75%, 80%, 85%, 90% (e.g., 92%, 93%, 94%) or higher, e.g., 95%, 96%, 97%, 98%, 99%, 99.5%, particularly for the sequence of the amino acids that provide the functional regions of the protein.

[00106] Also provided are proteins that are substantially identical to the wild type protein, where “substantially identical” means that the protein has an amino acid sequence identity to the sequence of wild type protein of at least about 60%, usually at least about 65%, and more usually at least about 70%, and in some instances the identity may be much higher, e.g., 75%, 80%, 85%, 90% (e.g., 92%, 93%, 94%), 95% or higher, e.g., 95%, 96%, 97%, 98%, 99%, 99.5%.

[00107] Proteins that are derivatives or mutants of the above-described naturally occurring proteins are also provided. Mutants may retain biological properties of the wild type (e.g., naturally occurring) proteins, or may have biological properties which differ from the wild type proteins. The term “biological property” of the proteins of the present invention refers to, but is not limited to, spectral properties, such as absorbance maximum, emission maximum, maximum extinction coefficient, brightness (e.g., as compared to the wild type protein or another reference protein such as green fluorescent protein (GFP) from *A. victoria*), and the like; *in vivo* and/or *in vitro* stability (e.g., half-life); and other such properties. Mutations include single amino acid changes, deletions of one or more amino acids, N-terminal truncations, C-terminal truncations, insertions, and the like.

[00108] Mutant proteins can be generated using standard techniques of molecular biology, e.g., random mutagenesis, and targeted mutagenesis as described earlier. Several mutants are described herein. Given the guidance provided in the Example, and using standard techniques, those skilled in the art can readily generate a wide variety of additional mutants and test whether a biological property has been altered. For example, fluorescence intensity can be measured using a spectrophotometer at various excitation wavelengths.

[00109] Those proteins of the subject invention that are naturally-occurring proteins are present in a non-naturally occurring environment, e.g., are separated from their naturally-occurring environment. In certain embodiments, the subject

proteins are present in a composition that is enriched for the subject protein as compared to its naturally-occurring environment. For example, purified protein is provided, where "purified" means that the protein is present in a composition that is substantially free of non-chromogenic or fluorescent proteins of interest, where "substantially free" means that less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of non-chromogenic or fluorescent proteins or mutants thereof. The proteins of the present invention also may be present as an isolate, by which is meant that the protein is substantially free of other proteins and other naturally-occurring biological molecules, such as oligosaccharides, polynucleotides and fragments thereof, and the like, where the term "substantially free" in this instance means that less than 70%, usually less than 60% and more usually less than 50% of the composition containing the isolated protein is some other natural occurring biological molecule. In certain embodiments, the proteins are present in substantially pure form, where by "substantially pure form" means at least 95%, usually at least 97% and more usually at least 99% pure.

[00110] In addition to the naturally-occurring proteins, polypeptides that vary from the naturally occurring proteins, e.g., the mutant proteins described above, are also provided. Generally such polypeptides include an amino acid sequence encoded by an open reading frame (ORF) of the gene encoding the subject wild type protein, including the full length protein and fragments thereof, particularly biologically active fragments and/or fragments corresponding to functional domains, and the like; including fusions of the subject polypeptides to other proteins or peptides. Fragments of interest will typically be at least about 10 amino acids in length, usually at least about 50 amino acids in length, and may be as long as 300 amino acids in length or longer, but will usually not exceed about 250 amino acids in length, where the fragment will have a stretch of amino acids that is identical to the subject protein of at least about 10 amino acids, and usually at least about 15 amino acids, and in many embodiments at least about 50 amino acids in length. In some embodiments, the subject polypeptides are about 25 amino acids, about 50, about 75, about 100, about 125, about 150, about 200, or about 250 amino acids in length, up to the entire length of the protein. In some embodiments, a protein fragment retains all or substantially all of the specific property of the wild type protein.

[00111] The subject proteins and polypeptides may be obtained from naturally-occurring sources or synthetically produced. For example, wild type proteins may be derived from biological sources which express the proteins, e.g., *Aequorea coerulea* the subject proteins may also be derived from synthetic means, for example, by expressing a recombinant gene or nucleic acid coding sequence encoding the protein of interest in a suitable host, as described above. Any convenient protein purification procedures may be employed, where suitable protein purification methodologies are described in Guide to Protein Purification, (Deutscher ed.) (Academic Press, 1990). For example, a lysate may be prepared from the original source and purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, and the like.

[00112] Antibody Compositions

[00113] Also provided are antibodies that bind specifically to the fluorescent proteins of the present invention. Suitable antibodies are obtained by immunizing a host animal with peptides comprising all or a portion of the protein. Suitable host animals include mice, rats, sheep, goats, hamsters, rabbits, and others. The immunogen may comprise the complete protein, or fragments and derivatives thereof. Preferred immunogens comprise all or a part of the protein, where the protein includes post-translation modifications found on the native target protein. Immunogens are produced in a variety of ways known in the art, for example, expression of cloned genes using conventional recombinant methods, or isolation directly from *Aequorea coerulea*.

[00114] For preparation of polyclonal antibodies, the first step involves immunization of the host animal with the peptide immunogen, where the peptide protein immunogen preferably will be in substantially pure form, comprising less than about 1% contaminant. The immunogen may comprise a complete protein, or fragments or derivatives thereof. To increase the immune response of the host animal, the target protein may be combined with an adjuvant, where suitable adjuvants include alum, dextran, sulfate, large polymeric anions, oil and water emulsions, Freund's adjuvant, Freund's complete adjuvant, and the like. The peptide immunogen also may be conjugated to synthetic carrier proteins or synthetic antigens.

[00115] The peptide immunogen is administered to the host, usually intradermally, with an initial dosage followed by one or more, usually at least two, additional booster dosages. Following immunization, the blood from the host will be collected where the blood serum is separated from the blood cells. The immunoglobulin present in the resultant antiserum may be purified using known methods, such as ammonium salt fractionation, DEAE chromatography, and the like.

[00116] Alternatively, monoclonal antibodies may be produced by conventional techniques. Generally, the spleen and/or lymph nodes of an immunized host animal provide a source of plasma cells. The plasma cells are immortalized by fusion with myeloma cells to produce hybridoma cells. Culture supernatant from individual hybridomas is screened using standard techniques to identify those producing antibodies with the desired specificity. Suitable animals for production of monoclonal antibodies to the human protein include mice, rats, hamsters and the like. To raise antibodies against the mouse protein, the animal will generally be a hamster, guinea pig, or rabbit. The antibody may be purified from the hybridoma cell supernatants or ascites fluid by conventional techniques, such as affinity chromatography using protein bound to an insoluble support like protein A sepharose.

[00117] The antibody may be produced as a single chain, instead of the normal multimeric structure. Single chain antibodies are described in Jost et al., J.B.C. 269:26267-73 (1994), and others. DNA sequences encoding the variable region of the heavy chain and the variable region of the light chain may be ligated to a spacer encoding at least about 4 amino acids of small neutral amino acids, including glycine and/or serine. The protein encoded by this fusion allows assembly of a functional variable region that retains the specificity and affinity of the original antibody.

[00118] Also of interest in certain embodiments are humanized antibodies. Methods of humanizing antibodies are known in the art. The humanized antibody may be the product of an animal having transgenic human immunoglobulin constant region genes (see for example International Patent Applications WO 90/10077 and WO 90/04036). Alternatively, the antibody of interest may be engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3, hinge domains,

and/or the framework domain with the corresponding human sequence (see WO 92/02190).

[00119] The use of immunoglobulin cDNA for construction of chimeric immunoglobulin genes is known in the art (Liu et al., Proceedings of the National Academy of Sciences 84:3439 (1987) and J. Immunol.139:3521 (1987)). Essentially, mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA. The cDNA of interest may be amplified by the polymerase chain reaction using specific primers (U.S. Patent Nos. 4,683,195 and 4,683,202). Alternatively, a library is made and screened to isolate the sequence of interest. The DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences. The sequences of human constant regions genes may be found in Kabat et al., "Sequences of Proteins of Immunological Interest", N.I.H. publication no. 91-3242 (1991). Human C region genes are readily available from known clones. The choice of isotype will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Preferred isotopes are IgG1, IgG3 and IgG4. Either of the human light chain constant regions, kappa or lambda, may be used. The chimeric, humanized antibody is then expressed by conventional methods.

[00120] Antibody fragments, such as Fv, F(ab')₂ and Fab may be prepared by cleavage of the intact protein, for example, by a protease or lay chemical cleavage. Alternatively, a truncated gene may be designed. For example, a chimeric gene encoding a portion of the F(ab')₂ fragment would indicate DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.

[00121] Consensus sequences of H and L J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.

[00122] Expression vectors include plasmids, retroviruses, YACs, EBV-derived episomes, and the like. A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, such as the SV-40 early promoter, (Okayama et al., Mol. Cell. Bio. 3:280 (1983)); Rous sarcoma virus LTR (Gorman et al., Proceedings of the National Academy of Sciences. 79:6777 (1982)); or moloney murine leukemia virus LTR (Grosschedl et al., Cell 41:885 (1985)); or native Ig promoters etc.

[00123] Transgenics

[00124] The nucleic acids of the present invention can be used to generate transgenic, non-human plants or animals or site-specific gene modifications in cell lines. Transgenic cells of the subject invention include one or more nucleic acids according to the subject invention present as a transgene, where included within this definition are the parent cells transformed to include the transgene and the progeny thereof. In many embodiments, the transgenic cells are cells that do not normally harbor or contain a nucleic acid according to the present invention. In those embodiments where the transgenic cells do naturally contain the subject nucleic acids, the nucleic acid will be present in the cell in a position other than its natural location, such as being integrated into the genomic material of the cell at a non-natural location. Transgenic animals may be made through homologous recombination, where the endogenous locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.

[00125] Transgenic organisms of interest include cells and multicellular organisms, both plants and animals, in which the protein or variants thereof is

expressed in cells or tissues where it is not normally expressed and/or at levels not normally present in such cells or tissues.

[00126] DNA constructs for homologous recombination will comprise at least a portion of a nucleic acid of the present invention, wherein the gene has the desired genetic modification(s), and includes regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection may be included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown et al., Meth. Enzymol. 185:527-37 (1990).

[00127] For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, such as a mouse, rat, guinea pig, etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of leukemia inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time is given for colonies to grow, the colonies are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4- to 6-week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting offspring are screened for the construct. Chimeric progeny can be readily detected if the phenotype of transformed cells differs in some way from the naturally occurring cells (such as exhibiting fluorescence).

[00128] The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, as is possible particularly with the fusion proteins of the present invention, tissues or

organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc., and used in functional studies, drug screening and the like. Representative examples of the use of transgenic animals include those described infra.

[00129] Transgenic plants also may be produced. Methods of preparing transgenic plant cells and plants are described in U.S. Patent Nos. 5,767,367; 5,750,870; 5,739,409; 5,689,049; 5,689,045; 5,674,731; 5,656,466; 5,633,155; 5,629,470; 5,595,896; 5,576,198; 5,538,879; 5,484,956; the disclosures of which are herein incorporated by reference. Methods of producing transgenic plants also are reviewed in Plant Biochemistry and Molecular Biology (eds. Lea and Leegood, John Wiley & Sons) pp. 275-295 (1993). In brief, a suitable plant cell or tissue is harvested, depending on the nature of the plant species. As such, in certain instances, protoplasts will be isolated, where such protoplasts may be isolated from a variety of different plant tissues, e.g., leaf, hypocotyl, root, etc. For protoplast isolation, the harvested cells are incubated in the presence of cellulases in order to remove the cell wall, where exact incubation conditions will vary depending on the type of plant and/or tissue from which the cell is derived. The resultant protoplasts are then separated from the resultant cellular debris by sieving and centrifugation.

[00130] Alternatively, embryogenic explants comprising somatic cells may be used for preparation of the transgenic host. Following cell or tissue harvesting, exogenous DNA of interest is introduced into the plant cells, where a variety of different techniques is available for such introduction. With isolated protoplasts, the opportunity arises for introduction via DNA-mediated gene transfer protocols, including incubation of the protoplasts with naked DNA, such as plasmids comprising the exogenous coding sequence of interest in the presence of polyvalent cations (for example, PEG or PLO); or electroporation of the protoplasts in the presence of naked DNA comprising the exogenous sequence of interest. Protoplasts that have successfully taken up the exogenous DNA are then selected, grown into a callus, and ultimately into a transgenic plant through contact with the appropriate amounts and ratios of stimulatory factors, such as auxins and cytokinins.

[00131] With embryonic explants, a convenient method of introducing the exogenous DNA into the target somatic cells is through the use of particle acceleration or "gene-gun" protocols. The resultant explants are then allowed to grow into chimeric plants, are cross-bred, and transgenic progeny are then obtained.

[00132] Instead of the naked DNA approaches described above, another method of producing transgenic plants is via *Agrobacterium*-mediated transformation. With *Agrobacterium*-mediated transformation, co-integrative or binary vectors comprising the exogenous DNA are prepared and then introduced into an appropriate *Agrobacterium* strain, e.g., *A. tumefaciens*. The resultant bacteria are then incubated with prepared protoplasts or tissue explants, such as a leaf disk, and a callus is produced. The callus is then grown under selective conditions, selected and subjected to growth media to induce root and shoot growth to ultimately produce a transgenic plant.

[00133] Methods of Use

[00134] The fluorescent proteins and peptides of the present invention find use in a variety of different applications. Representative uses for each of these types of proteins will be described below, where the uses described herein are merely exemplary and are in no way meant to limit the use of the proteins of the present invention to those described.

[00135] The first application of interest is the use of the subject proteins in fluorescence resonance energy transfer (FRET) methods. In these methods, the subject proteins serve as donor and/or acceptors in combination with a second fluorescent protein or dye, for example, a fluorescent protein as described in Matz et al., Nature Biotechnology 17:969-973 (1999); a green fluorescent protein from *Aequorea victoria* or fluorescent mutant thereof, for example, as described in U.S. Patent No. 6,066,476; 6,020,192; 5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445; 5,874,304, the disclosures of which are herein incorporated by reference; other fluorescent dyes such as coumarin and its derivatives, 7-amino-4-methylcoumarin and aminocoumarin; bodipy dyes; cascade blue; or fluorescein and its derivatives, such as fluorescein isothiocyanate and Oregon green;

rhodamine dyes such as Texas red, tetramethylrhodamine, eosins and erythrosins; cyanine dyes such as Cy3 and Cy5; macrocyclic chelates of lanthanide ions, such as quantum dye; and chemiluminescent dyes such as luciferases, including those described in U.S. Patent Nos. 5,843,746; 5,700,673; 5,674,713; 5,618,722; 5,418,155; 5,330,906; 5,229,285; 5,221,623; 5,182,202; the disclosures of which are herein incorporated by reference.

[00136] Specific examples of where FRET assays employing the subject fluorescent proteins may be used include, but are not limited to, the detection of protein-protein interactions, such as in a mammalian two-hybrid system, transcription factor dimerization, membrane protein multimerization, multiprotein complex formation; as a biosensor for a number of different events, where a peptide or protein covalently links a FRET fluorescent combination including the subject fluorescent proteins and the linking peptide or protein is, for example, a protease-specific substrate for caspase-mediated cleavage, a peptide that undergoes conformational change upon receiving a signal which increases or decreases FRET, such as a PKA regulatory domain (cAMP-sensor), a phosphorylation site (for example, where there is a phosphorylation site in the peptide or the peptide has binding specificity to phosphorylated/dephosphorylated domain of another protein), or the peptide has Ca^{2+} binding domain. In addition, fluorescence resonance energy transfer or FRET applications in which the proteins of the present invention find use include, but are not limited to, those described in: U.S. Patent Nos. 6,008,373; 5,998,146; 5,981,200; 5,945,526; 5,945,283; 5,911,952; 5,869,255; 5,866,336; 5,863,727; 5,728,528; 5,707,804; 5,688,648; 5,439,797; the disclosures of which are herein incorporated by reference.

[00137] The subject fluorescent proteins also find use as biosensors in prokaryotic and eukaryotic cells, such as a Ca^{2+} ion indicator; a pH indicator; a phosphorylation indicator; or as an indicator of other ions, such as magnesium, sodium, potassium, chloride and halides. For example, for detection of Ca^{2+} ions, proteins containing an EF-hand motif are known to translocate from the cytosol to membranes upon Ca^{2+} binding. These proteins contain a myristoyl group that is buried within the molecule by hydrophobic interactions with other regions of the protein. Binding of Ca^{2+} induces a conformational change exposing the myristoyl group which then is

available for the insertion into the lipid bilayer (called a "Ca²⁺-myristoyl switch"). Fusion of such a EF-hand containing protein to fluorescent proteins would make it an indicator of intracellular Ca²⁺ by monitoring the translocation from the cytosol to the plasma membrane by confocal microscopy. EF-hand proteins suitable for use in this system include, but are not limited to: recoverin, calcineurin B, troponin C, visinin, neurocalcin, calmodulin, parvalbumin, and the like.

[00138] For indicating pH, a system based on hisactophilins may be employed. Hisactophilins are myristoylated histidine-rich proteins known to exist in *Dictyostelium*. Their binding to actin and acidic lipids is sharply pH-dependent within the range of cytoplasmic pH variations. In living cells, membrane binding seems to override the interaction of hisactophilins with actin filaments. At pH ≤ 6.5 they locate to the plasma membrane and nucleus. In contrast, at pH 7.5 they evenly distribute throughout the cytoplasmic space. This change of distribution is reversible and is attributed to histidine clusters exposed in loops on the surface of the molecule. The reversion of intracellular distribution in the range of cytoplasmic pH variations is in accord with a pK of 6.5 of histidine residues. The cellular distribution is independent of myristoylation of the protein. By fusing fluorescent proteins to hisactophilin, the intracellular distribution of the fusion protein can be followed by laser scanning, confocal microscopy or standard fluorescence microscopy.

[00139] For such studies, quantitative fluorescence analysis can be done by performing line scans through cells (laser scanning confocal microscopy) or other electronic data analysis (e.g., using metamorph software (Universal Imaging Corp)) and averaging of data collected in a population of cells. Substantial pH-dependent redistribution of hisactophilin/fluorescent protein from the cytosol to the plasma membrane occurs within 1-2 minutes and reaches a steady state level after 5-10 minutes. The reverse reaction takes place on a similar time scale. As such, a hisactophilin-fluorescent protein fusion protein that acts in an analogous fashion can be used to monitor cytosolic pH changes in real time in live mammalian cells. Such methods have use in high throughput applications, for example, in the measurement of pH changes as a consequence of growth factor receptor activation (e.g., epithelial or platelet-derived growth factor), chemotactic stimulation/cell locomotion, in the

detection of intracellular pH changes as second messenger, in the monitoring of intracellular pH in pH manipulating experiments, and the like.

[00140] For detection of PKC activity, the reporter system exploits the fact that a molecule called MARCKS (myristoylated alanine-rich C kinase substrate) is a PKC substrate. MARCKS is anchored to the plasma membrane via myristoylation and a stretch of positively charged amino acids (ED-domain) that bind to the negatively-charged plasma membrane via electrostatic interactions. Upon PKC activation, the ED-domain becomes phosphorylated by PKC, thereby becoming negatively charged, and as a consequence of electrostatic repulsion MARCKS translocates from the plasma membrane to the cytoplasm (called the "myristoyl-electrostatic switch"). Fusion of the N-terminus of MARCKS from the the myristoylation motif to the ED-domain of MARCKS to the fluorescent proteins of the present invention provides a detector system for PKC activity. When phosphorylated by PKC, the fusion protein translocates from the plasma membrane to the cytosol. This translocation may be tracked by standard fluorescence microscopy or confocal microscopy, for example, by using Cellomics Inc., technology or other high content screening systems (such as those from Universal Imaging Corp., or Becton Dickinson). The above reporter system has application in high content screening for PKC inhibitors, and as an indicator for PKC activity inscreening assays for potential reagents that interfere with this signal tansduction pathway. Methods of using fluorescent proteins as biosensors also include those described in U.S. Patent Nos. 5,972,638; 5,824,485 and 5,650,135 (as well as the references cited therein) the disclosures of which are herein incorporated by reference.

[00141] The fluorescent proteins of the present invention also find use in applications involving the automated screening of arrays of cells expressing fluorescent reporting groups by using microscopic imaging and electronic analysis. Screening can be used for drug discovery and in the field of functional genomics where the subject proteins are used as markers of whole cells to detect changes in multicellular reorganization and migration, for example in the formation of multicellular tubules (blood vessel formation) by endothelial cells, migration of cells through the Fluoroblok Insert system (Becton Dickinson Co.), wound healing, or neurite outgrowth. Screening can also be employed where the proteins of the

present invention are used as markers fused to peptides (such as targeting sequences) or proteins that detect changes in intracellular location as an indicator for cellular activity, for example in signal transduction, such as kinase and transcription factor translocation upon stimuli. Examples include protein kinase C, protein kinase A, transcription factor NFkB, and NFAT; cell cycle proteins, such as cyclin A, cyclin B1 and cyclin E; protease cleavage with subsequent movement of cleaved substrate; phospholipids, with markers for intracellular structures such as the endoplasmic reticulum, Golgi apparatus, mitochondria, peroxisomes, nucleus, nucleoli, plasma membrane, histones, endosomes, lysosomes, or microtubules.

[00142] The proteins of the present invention also can be used in high content screening to detect co-localization of other fluorescent fusion proteins with localization markers as indicators of movements of intracellular fluorescent proteins/peptides or as markers alone. Examples of applications involving the automated screening of arrays of cells in which the subject fluorescent proteins find use include U.S. Patent No. 5,989,835; as well as WO 0017624; WO 00/26408; WO 00/17643; and WO 00/03246; the disclosures of which are herein incorporated by reference.

[00143] The fluorescent proteins of the present invention also find use in high throughput screening assays. The subject fluorescent proteins are stable proteins with half-lives of more than 24 hours. Also provided are destabilized versions of the subject fluorescent proteins with decreased half-lives that can be used as transcription reporters for drug discovery. For example, a protein according to the subject invention can be fused with a putative proteolytic signal sequence derived from a protein with shorter half-life, such as a PEST sequence from the mouse ornithine decarboxylase gene, a mouse cyclin B1 destruction box or ubiquitin, etc. For a description of destabilized proteins and vectors that can be employed to produce the same, see e.g., U.S. Patent No. 6,130,313; the disclosure of which is herein incorporated by reference. Promoters in signal transduction pathways can be detected using destabilized versions of the subject fluorescent proteins for drug screening such as, for example, AP1, NFAT, NFkB, Smad, STAT, p53, E2F, Rb, myc, CRE, ER, GR and TRE, and the like.

[00144] The proteins of the present invention can be used as photoactivated labels for precise *in vivo* photolabeling and following trafficking of proteins, organelles or cells as described in, for example, Patterson and Lippincott-Scott, Science, 13:1873-77 (2002) and Ando, et al., Proc. Natl. Acad. Sci. USA, 99:12651-56 (2002).

[00145] Additionally, the subject proteins can be used as second messenger detectors by fusing the subject proteins to specific domains such as the PKCgamma Ca binding domain, PKCgamma DAG binding domain, SH2 domain or SH3 domain, etc.

[00146] Secreted forms of the subject proteins can be prepared by fusing secreted leading sequences to the subject proteins to construct secreted forms of the subject proteins, which in turn can be used in a variety of different applications.

[00147] The subject proteins also find use in fluorescence activated cell sorting (FACS) applications. In such applications, the subject fluorescent protein is used as a label to mark a population of cells and the resulting labeled population of cells is then sorted with a fluorescent activated cell sorting device, as is known in the art. FACS methods are described in U.S. Patent Nos. 5,968,738 and 5,804,387; the disclosures of which are herein incorporated by reference.

[00148] The subject proteins also find use as *in vivo* markers in transgenic animals. For example, expression of the subject protein can be driven by tissue-specific promoters, where such methods find use in research for gene therapy, such as testing efficiency of transgenic expression, among other applications. A representative application of fluorescent proteins in transgenic animals that illustrates such applications is found in WO 00/02997, the disclosure of which is herein incorporated by reference.

[00149] Additional applications of the proteins of the present invention include use as markers following injection into cells or animals and in calibration for quantitative measurements; as markers or reporters in oxygen biosensor devices for monitoring cell viability; as markers or labels for animals, pets, toys, food, and the like.

[00150] The subject fluorescent proteins also find use in protease cleavage assays. For example, cleavage-inactivated fluorescence assays can be developed using the subject proteins, where the subject proteins are engineered to include a protease-specific cleavage sequence without destroying the fluorescent character of the protein. Upon cleavage of the fluorescent protein by an activated protease, fluorescence would sharply decrease due to the destruction of the functional chromophore. Alternatively, cleavage-activated fluorescence can be developed using the proteins of the present invention where the proteins are engineered to contain an additional spacer sequence in close proximity/or inside the chromophore. This variant is significantly decreased in its fluorescent activity, because parts of the functional chromophore are divided by the spacer. The spacer is framed by two identical protease-specific cleavage sites. Upon cleavage via the activated protease, the spacer would be cut out and the two residual "subunits" of the fluorescent protein would be able to reassemble to generate a functional fluorescent protein. Both of the above applications could be developed in assays for a variety of different types of proteases, such as caspases and others.

[00151] The subject proteins also can be used in assays to determine the phospholipid composition in biological membranes. For example, fusion proteins of the subject proteins (or any other kind of covalent or non-covalent modification of the subject proteins) that allows binding to specific phospholipids to localize/visualize patterns of phospholipid distribution in biological membranes, while allowing co-localization of membrane proteins in specific phospholipid rafts, can be accomplished with the subject proteins. For example, the PH domain of GRP1 has a high affinity to phosphatidyl-inositol tri-phosphate (PIP3) but not to PIP2. As such, a fusion protein between the PH domain of GRP1 and the subject proteins can be constructed to specifically label PIP3-rich areas in biological membranes.

[00152] Yet another application of the subject proteins is as a fluorescent timer, in which the switch of one fluorescent color to another (e.g., green to red) concomitant with the aging of the fluorescent protein is used to determine the activation/deactivation of gene expression, such as developmental gene expression,

cell cycle-dependent gene expression, circadian rhythm-specific gene expression, and the like.

[00153] The antibodies of the subject invention, described above, also find use in a number of applications, including the differentiation of the subject proteins from other fluorescent proteins.

[00154] Kits

[00155] Also provided by the present invention are kits for use in practicing one or more of the above-described applications, where the kits typically include elements for expressing the subject proteins, for example, a construct comprising a vector that includes a coding region for the subject protein. The kit components are typically present in a suitable storage medium, such as a buffered solution, typically in a suitable container. Also present in the kits may be antibodies to the provided protein. In certain embodiments, the kit comprises a plurality of different vectors each encoding the subject protein, where the vectors are designed for expression in different environments and/or under different conditions, for example, constitutive expression where the vector includes a strong promoter for expression in mammalian cells or a promoterless vector with a multiple cloning site for custom insertion of a promoter and tailored expression, etc.

[00156] In addition to the above components, the subject kits will further include instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information included in the packaging of the kit, such as a package insert. Yet another means would be a computer readable medium, e.g., diskette, CD, etc., on which the information has been recorded. Yet another means that may be present is a website address which may be used to access the information at a removed site via the internet. Any convenient means may be present in the kits.

[00157] The following example is offered by way of illustration and not by way of limitation.

[00158] Example

[00159] Several specimens of large hydromedusa were collected at the Russian coast of the Japan Sea near Vladivostok in August 2001. A set of characteristic features permits identification of these medusae as *Aequorea coerulescens* (Kramp, Dana Rept.,72:201-202 (1968); Pogodin and Yakovlev, Rus. J. Mar. Biol., 25:417-419 (1999)). Although *A. coerulescens* and *A. victoria* (synonyms of *A. forscalea*, *A. aequorea*) are similar, some of their features are very different. The most obvious difference is the number of tentacles: *A. victoria* carries only one tentacle per radial channel while *A. coerulescens* possesses 4-6 tentacles between each pair of adjacent radial channels.

[00160] The *A. coerulescens* specimens caught were bioluminescent. In contrast to *A. victoria*, they displayed a blue rather than green luminescence. No detectable fluorescence was observed in the *A. coerulescens* medusae in UV light or when using a fluorescent microscope. Nevertheless, a monoclonal antibody against *A. victoria* GFP detected a GFP-like protein in the protein extract from *A. coerulescens*. Figure 11 shows a protein gel-electrophoresis analysis of acGFP. Figure 11a is a Western blot analysis of soluble protein extract from *A. coerulescens* using antibodies against *A. victoria* GFP. Lane 1 is purified recombinant *A. victoria* GFP, Lane 2 is the *A. coerulescens* extract.

[00161] To clone the GFP-like protein, PCR was performed with degenerative primers corresponding to conservative amino acid sequences. A cDNA encoding a GFP-like protein was cloned. The nucleotide and amino acid sequence of the wildtype acGFP protein is shown in Figure 1. The acGFP protein demonstrated very high similarity to GFP, having a 92% amino acid sequence similarity; see Figure 2. All known key residues, including the chromophore-forming Ser65, Tyr66 and Gly67, the evolutionary invariant Arg96 and Glu222, and the residues spatially proximate to the chromophore, His148, Phe165, Ile167 and Thr203 were found unchanged in acGFP. Only three interior amino acids differed between these proteins.

[00162] Taking into account the very high sequence similarity, it was expected that the spectral properties of acGFP would be very similar to that of GFP. Nevertheless, *E. coli* colonies expressing acGFP showed neither fluorescence nor

coloration. The most simple explanation of this fact – unsatisfactory acGFP folding in *E. coli* – was only partially correct, as was demonstrated in further experiments.

[00163] The presence of acGFP cDNA in various parts of the medusa was tested by PCR using specific primers. Three cDNA samples corresponding to the umbrella border, radial channel, and oral disc of the medusa were tested. AcGFP cDNA was clearly detected in the umbrella border but was absent in two other samples. Thus, distribution of acGFP within the *A. coeruleus* is similar to the distribution of GFP in *A. victoria*, which forms a fluorescent ring in *A. victoria* umbrella border.

[00164] Random mutagenesis of acGFP produced many green fluorescent clones, some of which were characterized. Their properties and possible applications are similar to those for the enhanced GFP (EGFP) mutant of *A. victoria*.

[00165] Mutant Z1 contained one amino acid substitution, E222G (a glycine for a glutamic acid at position 222), as seen in Figure 3. The mutant Z1 protein possessed low brightness, very slow folding and required a temperature of less than 20°C for maturation. After growth at 30°C, *E. coli* colonies expressing Z1 must be stored for 3-5 days at room temperature or at 4°C for the fluorescence to become visible. Excitation and emission spectra for the Z1 mutant have maxima at 480 and 504 nm, respectively (see Figure 4).

[00166] Mutant Z2 contained two amino acid substitutions, specifically, N19D (an aspartic acid for an asparagine at position 19) and E222G (a glycine for a glutamic acid at position 222) as seen in Figure 5. The mutant Z2 possessed low brightness, very slow folding efficiency and required a temperature of less than 20°C for maturation. After overnight growth at 37°C, *E. coli* colonies expressing Z2 must be stored for 3-5 days at room temperature or at 4°C for the fluorescence to become visible. Excitation and emission spectra for the Z2 mutant are very similar to those of the mutant Z1.

[00167] Mutant G1 has substitutions V11I (an isoleucine for a valine at position 11), K101E (a glutamic acid for a lysine at position 101), and E222G (a glycine for a glutamic acid at position 222) as seen in Figure 6. Mutant G1 was generated in an independent round of random mutagenesis. Since substitution E222G was found in

three of the mutants, it seemed likely that this mutation was important for the green fluorescence of these mutants. Mutant G1 possesses rather low brightness. Fluorescence of this mutant becomes visible on the first day after overnight growth of the *E. coli*. The excitation and emission spectra of mutant G1 are very similar to those of the mutant Z1.

[00168] Mutant G2 has substitutions V11I (an isoleucine for a valine at position 11), F64L (a leucine for a phenylalanine at position 64), K101E (a glutamic acid for a lysine at position 101), and E222G (a glycine for a glutamic acid at position 222) as seen in Figure 7. Mutant G2 was generated based on mutant G1 using a second round of random mutagenesis. In comparison to G1, the G2 mutant protein possesses improved brightness and protein folding rate characteristics. Interestingly, G2 contains the substitution F64L that is also characteristic for enhanced GFP (EGFP) (Cormack et al., Gene, 173:33-38 (1996); Yang et al., Nuc. Acids Res., 24:4592-4593 (1996)). Spectral properties of G2 are shown in Table 1, infra. The excitation-emission spectra for G2 are shown in Figure 8.

[00169] Mutant G22 has substitutions V11I (an isoleucine for a valine at position 11), F64L (a leucine for phenylalanine at position 64), K101E (a glutamic acid for a lysine at position 101), T206A (an alanine for a threonine at position 206), and E222G (a glycine for a glutamic acid at position 222) as seen in Figure 9. Mutant G22 was generated from mutant G2 using a third round of random mutagenesis. In comparison to G2, G22 possesses even greater improved brightness. The spectral properties of G22 are reported in Table 1. The excitation-emission spectra for G22 are shown in Figure 10. An extinction coefficient of $50,000 \text{ M}^{-1}\text{cm}^{-1}$ and a quantum yield of 0.55 make this protein nearly as bright as the widely used enhanced GFP. Gel-filtration tests as well as SDS-PAGE of the non-heated mutant G22 protein demonstrated that G22 is monomeric. Figure 11B compares the mobility of heated (lanes 1-3) versus non-heated (lanes 4-6) protein samples. Lanes 1 and 4 are *A. victoria* GFP, lanes 2 and 5 are the G22 mutant, and lanes 3 and 6 are the G22-G222E mutant. Coomassie blue staining is shown on the left and fluorescence of the non-heated proteins under UV light is shown on the right.

[00170] All of the fluorescent mutants of acGFP mentioned above have similar excitation and emission spectra, peaking at 470-480 nm and 500-510 nm,

respectively. The shape of their excitation spectra are similar to that of enhanced GFP, but not wild type *A. victoria* GFP. It is likely that the fluorophore of the acGFP mutants is always in a deprotonated form, as it has been shown to be for enhanced GFP. A possible explanation is absence of Glu222, which may likely be important for proton transfer (Ehrig et al., FEBS Lett., 367:163-166 (1995)).

[00171] To clarify the importance of the E222G substitution for fluorescence, a reverse G222E substitution was made to the mutant G22 (substitutions V11I, F64L, K101E, T206A). The nucleic acid and amino acid sequences of this reverse mutant G22-E222G is shown in Figure 12. The reverse mutation readily transformed the G22-E222G mutant protein into a colorless state. *E. coli* colonies expressing G22-G222E displayed neither coloration nor detectable fluorescence.

[00172] G22-G222E was expressed and folded in *E. coli* at 37°C without a problem, as evidenced by the high yield of the soluble recombinant protein (about 20% of total proteins). Purified G22-G222E displayed an absorption spectrum with a major peak at 280 nm and a minor peak at 390 nm (see Figure 13A). Alkali-denatured G22-G222E protein showed absorption peak at 446 nm that apparently corresponds to the anionic form of the GFP chromophore. Assuming an extinction coefficient $44,000 \text{ M}^{-1}\text{cm}^{-1}$ for the chromophore, the extinction of native G22-G222E at 390 nm was estimated to be $33,000 \text{ M}^{-1}\text{cm}^{-1}$. The observed ratio between the 280-nm and 390-nm peaks (molar extinction coefficient at 280 nm was calculated to be $23,500 \text{ M}^{-1}\text{cm}^{-1}$) showed that only about 3% of soluble G22-G222E existed in a mature form. Excitation at 390 nm led to a weak dual-color fluorescence peaking at 460 nm and 505 nm with a quantum yield of 0.07 (see Figure 13B).

[00173] It is well-known that GFP-like proteins retain their spectral properties and oligomerization state under conditions of common SDS-PAGE as long as the protein samples are not heated before being loading onto the gel. This test was used to examine the folding state of G22-G222E. Gel-electrophoresis demonstrated a clear difference in the mobility of non-denatured and denatured proteins (see Figure 11). In addition, the non-heated G22-G222E protein band produced very weak fluorescence under UV light (again, see Figure 11). As about 97% of this protein is present in a non-absorbing form, these results indicate that the conformation of this non-absorbing form is close to the native state, but not to the denatured state.

[00174] Encouraged by these results, the attempts to obtain and characterize the recombinant wild type acGFP were repeated. Growth of *E. coli* expressing acGFP at room temperature without induction, followed by a several days incubation at 4°C, resulted in the appearance of a small fraction of soluble acGFP (about 5% of total acGFP). Shapes of the absorption and fluorescence spectra for the soluble wild type acGFP were very similar to that of G22-G222E. It was concluded that G22-G222E mutant mirrors the properties of the natural acGFP but possesses improved protein folding and temperature stability when expressed in *E. coli*.

[00175] These data showed that soluble G22-G222E as well as the wild type acGFP exists in two forms. The majority of these proteins are present in a folded but immature form without a spectrally-detectable chromophore. The minor 390 nm-absorbing form contains a GFP-like chromophore in a neutral state and possesses weak dual-color fluorescence.

[00176] A novel type of photoconversion was observed in mutant G22-G222E. Irradiation of a G22-G222E protein sample with 250-300 nm UV light resulted in the appearance of a 480 nm peak in the absorption/excitation spectra. Note in Figure 14 the excitation spectrum of G22-G222E before irradiation (line1) and the gradual change of the curve due to irradiation of the protein sample with light at 250-300 nm. The unnumbered line represents the emission spectrum after photoconversion (excitation at 480 nm). This may originate from an immature, spectrally undetectable form of the protein, as the 390 nm absorption peak did not decrease during this photoconversion. Excitation at the 480 nm peak produced green fluorescence at 505 nm with a high quantum yield (0.45). A greater than 1000-fold UV-induced enhancement of green fluorescence intensity was achieved (excitation at 480 nm).

[00177] Mutant G22-G222E/Y220L has substitutions V11I (an isoleucine for a valine at Position 11), F64L (a leucine for a phenylalanine at position 64), Vg8A (an alanine for a valine at position 68) K101E (a glutamic acid for a lysine at position 101), T206A (an alanine for a threonine at position 206), and Y220L (a leucine for a tyrosine at position 220) compared to the wild type acGFP, as seen in Figure 15. This mutant demonstrated protein folding at 37°C and possessed clear green fluorescence at 508 nm. The excitation spectrum for the G22-G222E/Y220L had a major peak at 396 nm and a minor peak at 493 nm (ratio 10:1) (see Figure 16 where

the excitation spectra is the dotted line and the emission spectra is the solid line). Spectral properties of this mutant were very similar to that of wild type GFP from *Aequorea victoria*.

[00178] Using mutant G22-G222E/Y220L as a basis, mutant 220-II-5 was obtained having substitutions V11I (an isoleucine for a valine at Position 11), F64L (a leucine for a phenylalanine at position 64), K101E (a glutamic acid for a lysine at position 101), E115K (a lysine for a glutamic acid at position 115), H148Q (a glutamine for a histidine at position 148), T206A (an alanine for a threonine at position 206), Y220L (a leucine for a tyrosine at position 220), F221L (a leucine for a phenylalanine at position 221), and K238Q (a glutamine for a lysine at position 238). The nucleic acid and amino acid sequences for this mutant are in Figure 17. Thus mutant has a major excitation peak at 395 nm, and no excitation peak at about 480 nm, with the emission peak at 512 nm (see Figure 18A). It is likely that the suppression of the longer-wavelength excitation peak can be explained by the substitution H148Q that results in a disappearance of the fraction of charged chromophore. After several minutes of relatively intense irradiation with light at approximately 400 nm under a fluorescent microscope, the excitation spectrum of mutant G22-G222E/Y220L changed. There was a simultaneous decrease of the 395 nm peak and appearance of the 480 nm excitation peak (see Figure 18B). As a result, a more than 100-fold contrast in the fluorescent brightness of the 510 nm emission can be obtained in the 480 nm excitation light, as compared to before and after irradiation of intense light of 400 nm wavelength. Figure 25 shows two *E. coli* colonies expressing mutant 220-11-5 under a fluorescent microscope. The two areas in the upper colony were photoactivated preliminarily by an intense 400 nm light. As such, the G22-G22E/Y220L mutants can be used as a photoactivated fluorescent marker for photo-labeling living organisms similar to the recently published methods for use of PA-GFP mutant in Patterson and Lippincott-Schwartz, Science,13:1873-1877 (2002).

[00179] Cyan fluorescent protein mutant CFP-rand3 has substitutions at V11I (isoleucine for valine at position 11), T62A (alanine for threonine at position 62), F64L (leucine for phenylalanine at position 64), K101E (glutamic acid for lysine at position 101), N121S (serine for asparagine at position 121), H148T (threonine for

histidine at position 148), E172K (lysine for glutamic acid at position 172), and T206A (alanine for threonine at position 206). The amino and nucleic acid sequences for the CFP-rand3 mutant are shown in Figure 19. This mutant has an excitation peak at 402 nm, with a single emission peak at 467 nm (see Figure 20).

[00180] Another mutant cyan fluorescent protein, CFP-3, was generated having substitutions V11I (isoleucine for valine at position 11), F64L (a leucine for a phenylalanine at position 64), K101E (glutamic acid for lysine at position 101), H148S (serine for histidine at position 148), F165L (leucine for phenylalanine at position 165), E172A (alanine for glutamic acid at position 172), and T206A (alanine for threonine at position 206). The amino and nucleic acid sequences for this mutant are shown in Figure 21. This mutant has an excitation peak at 390 nm, with a single emission peak at 470 nm Figure 22A. After several minutes of relatively intense irradiation with light at 400 nm, the following changes of excitation and emission spectra were observed: (i) considerable decrease in the 390-nm excitation peak, and (ii) appearance of a 480 nm excitation peak with emission at 505 nm (see Figure 22B).

[00181] As a result, a more than 30-fold contrast in the fluorescent brightness of the 505 nm emission may be obtained using excitation light at 480 nm, comparing the spectra before and after intense irradiation at 405 nm. Simultaneous change of the excitation and emission parameters transforms the cyan mutant CFP-3 to a green fluorescent protein in response to intense 400 nm irradiation. Therefore, the CFP-3 mutant can be used as a photoactivated or "photo-switched" fluorescent marker for photo-labeling of living organisms.

[00182] In one exemplary experiment, the G22 mutant was used as a fluorescent tag to test protein expression in mammalian cells. Unexpectedly, however, mutant G22 produced a very low fluorescent signal in human cell lines. This likely can be explained by either non-optimal codon usage or by presence of a cryptic intron in the G22 mutant gene. To overcome both these problems, a G22-h mutant gene was synthesized incorporating mammalian-optimized codon usage. The amino and nucleic acid sequences for this humanized mutant are shown in Figure 23. Transient expression of G22-h in different cell lines showed a bright green signal without aggregation.

[00183] Figure 24 shows transient expression of the G22-h mutant (panels A-E), and a G22- β -actin fusion protein (panel F) in different mammalian cell lines. Panel A-293T; panel B-vero; panel C-3T3; panel D-L929; panel E-COS1; panel F-3T3. Fluorescence was clearly detectable 24 hours post-transfection. No toxicity was observed. The ability of G22-h to tag proteins was demonstrated by constructing a fusion protein with cytoplasmic β -actin. Transient expression of this fusion in 3T3 cells showed bright and accurate actin labeling (see Figure 24F). Stress fibers, focal contacts and cell possesses were clearly visible. There was no observed detriment to cell adhesion or vitality, nor was any non-specific protein aggregation observed.

[00184] Methods:

[00185] Total RNA was isolated using a NucleoSpin RNA II kit (Clontech) from a small vivsection of an *Aequorea coerulescens* organism that included umbrella border and radial channel. cDNA was synthesized and amplified with a SMART PCR cDNA Synthesis kit (Clontech). A fragment of the novel fluorescent protein gene was obtained by PCR with degenerated primers. A step-out PCR RACE method was used to clone the 5'-end fragment of the target cDNA. The nucleotide sequence of the cDNA encoding the novel fluorescent protein, acGFP, has been submitted to GenBank with accession number AY151052. For bacterial expression of acGFP, the full-length coding region was amplified using specific primers and cloned into the pQE30 vector (Qiagen).

[00186] A Diversity PCR Random Mutagenesis kit (CLONTECH) was used for random mutagenesis of acGFP, in conditions optimal for 5-6 mutations per 1000 basepairs. *E. coli* colonies expressing mutant proteins were screened visually with a fluorescent stereomicroscope SZX-12 (Olympus). The brightest variants were selected and subjected an additional round of random mutagenesis. Site-directed mutagenesis was performed by PCR using the overlap extension method, with primers containing appropriate target substitutions (see, for example, Ho et al., Gene, 77:51-59 (1989)).

[00187] Proteins fused to an N-terminal six-histidine tag were expressed in *E. coli* XL1 blue strain (Invitrogen) and purified using TALON metal-affinity resin (Clontech). Absorption spectra were recorded with a Beckman DU520 UV/VIS

Spectrophotometer. A Varian Cary Eclipse Fluorescence Spectrophotometer was used for measuring excitation-emission spectra.

[00188] For molar extinction coefficient determination, estimation of mature chromophore concentration was used. Proteins were alkali-denatured with an equal volume of 2M NaOH. Under these conditions, the *A. victoria* GFP chromophore absorbs at 446 nm and its molar extinction coefficient equals $44,000 \text{ M}^{-1}\text{cm}^{-1}$ (Ward et al., Photochem. Photobiol., 31:611-615 (1980)). Absorption spectra for native and alkali-denatured proteins were measured. The molar extinction coefficients for the native state were estimated using the absorption of denatured proteins as a basis. For quantum yield determination, the fluorescence of the mutants was compared to that of enhanced GFP (quantum yield 0.60).

[00189] UV-induced photoconversion of acGFP-G222E was performed using a Cary Eclipse Fluorescence Spectrophotometer. The protein sample was irradiated for several hours with 250-300 nm wavelength light in scanning mode (excitation slit 20 nm, scan rate 30 nm/min, averaging time 1 second, cycle mode).

[00190] Purified protein samples (~1 mg/ml) were loaded onto a Sephadex-100 column (0.7 x 60 cm) and eluted with 50 mM phosphate buffer (pH 7.0) with 100 mM NaCl. EGFP, HcRed1, and DsRed2 (Clontech) were used as monomer, dimer and tetramer standards, respectively.

[00191] For protein gel analysis, heated and unheated samples were loaded onto a common 12% SDS-PAGE, and electrophoresis was carried out at 15 mA/gel. For Western blotting, proteins were transferred onto a Hybond C membrane (Amersham) using standard procedures. Membranes were probed with mouse antibodies (Clontech) against GFP (1:2500), and then with HRP-conjugated anti-mouse antibodies (Amersham) at 1:2500. To develop the staining pattern, an ECL Western blotting analysis system (Amersham Pharmacia Biotech) was used, including detection reagents 1, 2 and Hyperfilm ECL.

[00192] For expression in eukaryotic cells, acGFP was cloned into pEGFP-C1 and pEGFP-Actin vectors (CLONTECH) between *Age*I and *Bgl*II restriction sites (in lieu of the EGFP coding region). The following cell lines were used: human kidney epithelial cells 293T, mouse embryo fibroblasts 3T3, murine subcutaneous

fibroblasts L929, African green monkey kidney epithelial cells Vero, and African green monkey kidney fibroblasts COS1. Cells were transfected with LipofectAMINE reagent (Invitrogen) and were tested 20 hours after transfection. An Olympus CK40 fluorescent microscope equipped with CCD camera DP-50 (Olympus) was used for cell imaging.

Table 1. Spectral properties of acGFP mutants in comparison with EGFP.

Species	Protein name	Absorption max, nm	Emission max, nm	Maximal extinction coefficient, $M^{-1}cm^{-1}$	Quantum yield	Relative brightness**
<i>Aequorea victoria</i>	EGFP*	488	509	53,000	0.60	1
<i>Aequorea coerulea</i>	Wild type acGFP	390	460, 505	nt	nt	nt
	Mutant G2	475	504	58,000	0.38	0.69
	Mutant G22	480	505	50,000	0.55	0.86
	Mutant G22-G22E***	390	460, 505	33,000	0,07	0,07
	Mutant CFP-rand3	402	467	35,000	0.30	0.33

* Data from reference: Patterson, G., Day, R.N., and Piston, D. (2001) Fluorescent protein spectra. J. Cell. Sci. 114, 837-838

** As compared to the brightness (extinction coefficient multiplied by quantum yield) of EGFP.

*** Data on mature fraction of the mutant (about 3% from the total protein)

[00193] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

[00194] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

AMENDED CLAIMS

[received by the International Bureau on 17 November 2003 (17.11.03);
original claims 1-20 replaced by new claims 1-32 (3 pages)]

1. An isolated nucleic acid which encodes an *Aequorea coerulescens* peptide, selected from:
 - (a) a nucleic acid which encodes a protein comprising an amino acid sequence SEQ ID NO: 02;
 - (b) a nucleic acid comprising a nucleotide sequence SEQ ID NO: 01.
2. An isolated nucleic acid selected from the group consisting of:
 - (a) a nucleic acid derived from the nucleic acid of claim 1 using at least one of site-directed mutagenesis and/or random mutagenesis;
 - (b) a nucleic acid coding for an amino acid sequence selected from SEQ ID NOs: 04, 06, 08, 10, 12, 14, 16, 18, 20, 22, or 24; or
 - (c) a nucleic acid comprising a nucleotide sequence selected from SEQ ID NOs: 03, 05, 07, 09, 11, 13, 15, 17, 19, 21, or 23.
 - (d) a nucleic acid differing from the nucleic acid of (a) above due to degeneracy of the genetic code
3. An isolated nucleic acid of claim 2, wherein said nucleic acid encodes a fluorescent protein
4. An expression cassette comprising
 - (a) the nucleic acid of claim 2; and
 - (b) regulatory elements necessary for expression of the nucleic acid in the cell.
5. An expression cassette comprising
 - (a) the nucleic acid of claim 3; and
 - (b) regulatory elements necessary for expression of the nucleic acid in the cell.
6. A cell, or progeny thereof, comprising the expression cassette of

AMENDED CLAIMS

claim 4.

7. A cell, or progeny thereof, comprising the expression cassette of claim 5.

8. An isolated peptide encoded by the nucleic acid of claim 2.

9. An antibody binding specifically to the peptide of claim 8.

10. A fusion peptide incorporating the peptide of claim 8.

11. A transgenic organism capable of expressing the peptide of claim 8.

12. A method for labeling or detecting a biological molecule comprising coupling said biological molecule to the peptide of claim 8.

13. A method for labeling or detecting a cell or cell organelle comprising production of the peptide of claim 8 in the cell.

14. A method for detecting a gene expression comprising production of the peptide of claim 8 in the cell.

15. An isolated peptide encoded by the nucleic acid of claim 3.

16. An antibody binding specifically to the peptide of claim 15.

17. A fusion peptide incorporating the peptide of claim 15.

18. A transgenic organism capable of expressing the peptide of claim 15.

19. A method for labeling or detecting a biological molecule comprising coupling said biological molecule to the peptide of claim 15.

20. A method for labeling or detecting a cell or cell organelle comprising production of the peptide of claim 15 in the cell.

21. A method for detecting a gene expression comprising production of the peptide of claim 15 in the cell.

22. A nucleic acid fragment, wherein said fragment is selected from the group consisting of:

AMENDED CLAIMS

(a) a fragment encoding a peptide of at least 100 amino acid residues in length from SEQ ID NOs: 02, 04, 06, 08, 10, 12, 14, 16, 18, 20, 22, or 24; or

(b) a fragment substantially similar or identical to a nucleotide sequence of at least 300 residues in length from SEQ ID NO: 01, 03, 05, 07, 09, 11, 13, 15, 17, 19, 21, or 23.

23. A nucleic acid molecule comprising a nucleic acid fragment of claim 22, wherein the nucleic acid encodes a fluorescent protein

24. An expression cassette comprising

(a) the nucleic acid molecule of claim 23; and

(b) regulatory elements necessary for expression of the nucleic acid fragment in the cell.

25. A cell, or progeny thereof, comprising the expression cassette of claim 24.

26. An isolated peptide encoded by the nucleic acid fragment of claim 23.

27. An antibody binding specifically to the peptide of claim 26.

28. A fusion peptide incorporating the peptide of claim 26.

29. A transgenic organism capable of expressing the peptide of claim 26.

30. A method for labeling or detecting a biological molecule comprising coupling said biological molecule to the peptide claim 26.

31. A method for labeling or detecting a cell or cell organelle comprising production of the peptide of claim 26 in the cell.

32. A method for detecting a gene expression comprising production of the peptide of claim 26 in a cell.

1/23

10 20 30 40 50 60
 5' ATTCAAAACACTGCAGAATTTTGGATAGATTTTCCTGCTACTTCACACGCATAAAAGACA

 70 80 90 100 110 120
 AGAAAGATGAGTAAAGGAGCAGAACTTTTCACTGGAGTTGTCCCAATTCTTATTGAATTA
 M S K G A E L F T G V V P I L I E L

 130 140 150 160 170 180
 AATGGTGATGTTAATGGGCACAAATTTCTCTGTCAGTGGAGAGGGCGAAGGTGATGCGACA
 N G D V N G H K F S V S G E G E G D A T

 190 200 210 220 230 240
 TACGGAAAGTTAACCCCTTAAATTTATTTGCACTACAGGAAAACCTGTTCCATGGCCA
 Y G K L T L K F I C T T G K L P V P W P

 250 260 270 280 290 300
 ACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATATCCAGATCATATG
 T L V T T F S Y G V Q C F S R Y P D H M

 310 320 330 340 350 360
 AACAGCATGACTTCTTCAAGAGTGCCATGCCTGAAGGTTATATACAGGAAAGAACTATA
 K Q H D F F K S A M P E G Y I Q E R T I

 370 380 390 400 410 420
 TTTTTCAAAGATGACGGGAACTACAAGTCGCGTGCTGAAGTCAAGTTCGAAGGTGATACC
 F F K D D G N Y K S R A E V K F E G D T

 430 440 450 460 470 480
 CTGGTTAATAGAATTGAGTTAACAGGTACTGATTTTAAAGAAGATGGAAACATCCTTGGA
 L V N R I E L T G T D F K E D G N I L G

 490 500 510 520 530 540
 AATAAAATGGAATACAACCTATAACGCACATAATGTATACATCATGACAGACAAAGCAAAA
 N K M E Y N Y N A H N V Y I M T D K A K

 550 560 570 580 590 600
 AATGGAATCAAAGTTAACTTCAAATTTAGACACAACATTTGAAGATGGAAGCGTTCAACTT
 N G I K V N F K I R H N I E D G S V Q L

 610 620 630 640 650 660
 GCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGATAAC
 A D H Y Q Q N T P I G D G P V L L P D N

 670 680 690 700 710 720
 CATTACCTGTCCACACAATCTACCCTTTCCAAAGATCCCAACGAAAAGAGAGATCACATG
 H Y L S T Q S T L S K D P N E K R D H M

 730 740 750 760 770 780
 ATCTATTTTGAGTTTGTAAACAGCTGCTGCGATTACACATGGCATGGATGAATTATACAAA
 I Y F E F V T A A A I T H G M D E L Y K

 790 800 810 820 830 840
 TAAATGTATAGACTTCAAGTTGACACTAACGTGTCCGAACAATTAATAAAATCTCAGGGT

 850 860 870 880 890 900
 TCCTGGTTAAAATCAGGCTGAGATATTATTTACATATTATAGATTCATTAGAATTATTTA

 910 920 930 940
 AATACTTTATAGATGTTATTGATAGGGGTTATTTTCTTATT 3'

FIG. 1

3/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA GCT GIC CCA ATT CTT ATT	48
1	M S K G A E L F T G A V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GIC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GIC ACT ACT TTC	192
49	T T G K L P V P W P T L V T T F	64
193	TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TIC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA ACA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TIC AAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GIC	336
97	T I F F K D D G N Y K S R A E V	112
337	AAG TIC GAA GGT GAT ACC CIG GGT AAT AGA ATT GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A H N V Y I M T D K A K N G	160
481	ATC AAA GTT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA ACC GTT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GIC CTT TTA CCA GAT AAC CAT TAC CIG TCC ACA CAA TCT ACC CTT TCC	624
193	V L L P D N H Y L S T Q S T L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GGG TTT GTA	672
209	K D P N E K R D H M I Y F G F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA TTA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 3

4/23




FIG. 4




FIG. 8

5/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA GCT GTC CCA ATT CTT ATT	48
1	M S K G A E L F T G A V P I L I	16
49	GAA TTA GAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GTC AGT GGA GAG	96
17	E L D G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GTC ACT ACT TTC	192
49	T T G K L P V P W P T L V T T F	64
193	TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TTC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TTC AAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GTC	336
97	T I F F K D D G N Y K S R A E V	112
337	AAG TTC GAA GGT GAT ACC CTG GGT AAT AGA ATT GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A H N V Y I M T D K A K N G	160
481	ATC AAA GGT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC GGT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT ACC CTT TCC	624
193	V L L P D N H Y L S T Q S T L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GGG TTT GTA	672
209	K D P N E K R D H M I Y F G F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA TTA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 5

6/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GIC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GIC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA TGA CCT GGT CCA TGG CCA ACA CTT GIC ACT ACT	192
49	T T G K L * P V P W P T L V T T	64
193	TTC TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA	240
65	F S Y G V Q C F S R Y P D H M K	80
241	CAG CAT GAC TTC TTC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA	288
81	Q H D F F K S A M P E G Y I Q E	96
289	AGA ACT ATA TTT TTC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA	336
97	R T I F F E D D G N Y K S R A E	112
337	GIC AAG TTC GAA GGT GAT ACC CTG GGT AAT AGA ATT GAG TTA ACA GGT	384
113	V K F E G D T L V N R I E L T G	128
385	ACT GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC	432
129	T D F K E D G N I L G N K M E Y	144
433	AAC TAT AAC GCA CAT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT	480
145	N Y N A H N V Y I M T D K A K N	160
481	GGA ATC AAA GGT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC	528
161	G I K V N F K I R H N I E D G S	176
529	GGT CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC	576
177	V Q L A D H Y Q Q N T P I G D G	192
577	CCT GIC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT ACC CTT	624
193	P V L L P D N H Y L S T Q S T L	208
625	TCC AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GGG TTT	672
209	S K D P N E K R D H M I Y F G F	224
673	GTA ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA TTA TAC AAA TAA	720
225	V T A A A I T H G M D E L Y K *	240

FIG. 6

7/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GTC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GTC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GTC ACT ACT CTT	192
49	T T G K L P V P W P T L V T T I	64
193	TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TTC AAG AGT GGC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TTC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GTC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TTC GAA GGT GAT ACC CTG GGT AAT AGA ATT GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A H N V Y I M T D K A K N G	160
481	ATC AAA GGT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA ACC GGT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT ACC CTT TCC	624
193	V L L P D N H Y L S T Q S T L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GGG TTT GTA	672
209	K D P N E K R D H M I Y F G F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA TTA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 7

8/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GIC CCA ATT CTT AIT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GIC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CIA CCT GGT CCA TGG CCA ACA CTT GIC ACT ACT CTT	192
49	T T G K L P V P W P T L V T T L	64
193	TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT AIG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TTC AAG AGT GCC AIG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TTC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GIC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TTC GAG GGT GAT ACC CTG GGT AAT AGA AIC GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC AIC CTT GGA AAT AAA AIG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAT AAT GTA TAC AIC AIG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A H N V Y I M T D K A K N G	160
481	AIC AAA GIT AAC TTC AAA AIT AGA CAC AAC AIT GAA GAT GGA AGC GIT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA AIT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GIC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT GGC CTT TCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC AIG AIC TAT TTT GGG TTT GTA	672
209	K D P N E K R D H M I Y F G F V	224
673	ACA GCT GCT GCG AIT ACA CAT GGC AIG GAT GAA CIA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 9




FIG. 10




FIG. 16

10/23




FIG. 11a




FIG. 11b

FIG. 11c

11/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GTC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GTT AAT GGG CAC AAA TTC TCT GTC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GTC ACT ACT GTC	192
49	T T G K L P V P W P T L V T T I	64
193	TCT TAT GGT GTT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TTC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TTC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GTC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TTC GAG GGT GAT ACC CTG GTT AAT AGA ATC GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A H N V Y I M T D K A K N G	160
481	ATC AAA GTT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC GTT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GAG TTT GTA	672
209	K D P N E K R D H M I Y F E F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 12

12/23




FIG. 13a




FIG. 13b




FIG. 14

14/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GTC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TIC TCT GTC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GTC ACT ACT CTC	192
49	T T G K L P V P W P T L V T T L	64
193	TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TTC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TTC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GTC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TTC GAG GGT GAT ACC CIG GGT AAT AGA ATC GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A H N V Y I M T D K A K N G	160
481	ATC AAA GGT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC GGT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTC CTT TTA CCA GAT AAC CAT TAC CIG TCC ACA CAA TCT GCC CTT TCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC CIG TTT GAG TTT GTA	672
209	K D P N E K R D H M I L F E F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 15

15/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GTC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GTC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GTC ACT ACT GTC	192
49	T T G K L P V P W P T L V T T L	64
193	TCT TAT GGT GCT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G A Q C F S R Y P D H M K Q	80
241	CAT GAC TIC TIC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TTC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GTC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TTC AAG GGT GAT ACC CTG GGT AAT AGA ATC GAG TTA ACA GGT ACT	384
113	K F K G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA CAG AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A Q N V Y I M T D K A K N G	160
481	ATC AAA GGT AAC TIC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC GGT	528
161	I K V N F K I R H N I E D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC CTG CTG GAG TTT GTA	672
209	K D P N E K R D H M I L L E F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA CTA TAC CAA TAA	717
225	T A A A I T H G M D E L Y Q *	239

FIG. 17

16/23




FIG. 18a




FIG. 18b

17/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GIC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GTT AAT GGG CAC AAA TTC TCT GIC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GIC GCT ACT CTC	192
49	T T G K L P V P W P T L V A T L	64
193	TCT TAT GGT GTT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TTC TTC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TIC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GIC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TTC GAG GGT GAT ACC CTG GTT AGT AGA ATC GAG TTA ACA GGT ACT	384
113	K F E G D T L V S R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA ACT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A T N V Y I M T D K A K N G	160
481	ATC AAA GTT AAC TTC AAA ATT AGA CAC AAC ATT AAA GAT GGA AGC GTT	528
161	I K V N F K I R H N I K D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GIC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT GGC CTT TCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GAG TTT GTA	672
209	K D P N E K R D H M I Y F E F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA TAA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 19

18/23




FIG. 20

19/23

1	ATG AGT AAA GGA GCA GAA CTT TTC ACT GGA ATT GTC CCA ATT CTT ATT	48
1	M S K G A E L F T G I V P I L I	16
49	GAA TTA AAT GGT GAT GGT AAT GGG CAC AAA TTC TCT GTC AGT GGA GAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGC GAA GGT GAT GCG ACA TAC GGA AAG TTA ACC CTT AAA TTT ATT TGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACT ACA GGA AAA CTA CCT GGT CCA TGG CCA ACA CTT GTC ACT ACT GTC	192
49	T T G K L P V P W P T L V T T L	64
193	TCT TAT GGT GGT CAA TGC TTT TCA AGA TAT CCA GAT CAT ATG AAA CAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CAT GAC TIC TIC AAG AGT GCC ATG CCT GAA GGT TAT ATA CAG GAA AGA	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACT ATA TTT TIC GAA GAT GAC GGG AAC TAC AAG TCG CGT GCT GAA GTC	336
97	T I F F E D D G N Y K S R A E V	112
337	AAG TIC GAG GGT GAT ACC CTG GGT AAT AGA ATC GAG TTA ACA GGT ACT	384
113	K F E G D T L V N R I E L T G T	128
385	GAT TTT AAA GAA GAT GGA AAC ATC CTT GGA AAT AAA ATG GAA TAC AAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TAT AAC GCA TGT AAT GTA TAC ATC ATG ACA GAC AAA GCA AAA AAT GGA	480
145	Y N A S N V Y I M T D K A K N G	160
481	ATC AAA GGT AAC TIG AAA ATT AGA CAC AAC ATT GCA GAT GGA AGC GGT	528
161	I K V N L K I R H N I A D G S V	176
529	CAA CTT GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTC CTT TTA CCA GAT AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAA GAT CCC AAC GAA AAG AGA GAT CAC ATG ATC TAT TTT GAG TTT GTA	672
209	K D P N E K R D H M I Y F E F V	224
673	ACA GCT GCT GCG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA TAA	717
225	T A A A I T H G M D E L I K *	239

FIG. 21

20/23




FIG. 22a




FIG. 22b

21/23

1	ATGAGCAAGGGCGCCGAGCTGTTACCGGCATCGTGCCCATCCTGATC	48
1	M S K G A E L F T G I V P I L I	16
49	GAGCTGAATGGCGATGTGAATGGCCACAAGTTCAGCGTGAGCGGCGAG	96
17	E L N G D V N G H K F S V S G E	32
97	GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGC	144
33	G E G D A T Y G K L T L K F I C	48
145	ACCACCGGCAAGCTGCCTGTGCCCTGGCCCACCCTGGTGACCACCCTG	192
49	T T G K L P V P W P T L V T T L	64
193	AGCTACGGCGTGCAGTGCTTCTCACGCTACCCCGATCACATGAAGCAG	240
65	S Y G V Q C F S R Y P D H M K Q	80
241	CACGACTTCTTCAAGAGCGCCATGCCTGAGGGCTACATCCAGGAGCGC	288
81	H D F F K S A M P E G Y I Q E R	96
289	ACCATCTTCTTCGAGGATGACGGCAACTACAAGTCGCGCGCCGAGGTG	336
97	T I F F E D D G N Y K S R A E V	112
337	AAGTTCGAGGGCGATAACCTGGTGAATCGCATCGAGCTGACCGGCACC	384
113	K F E G D T L V N R I E L T G T	128
385	GATTTCAAGGAGGATGGCAACATCCTGGGCAATAAGATGGAGTACAAC	432
129	D F K E D G N I L G N K M E Y N	144
433	TACAACGCCCAATGTGTACATCATGACCGACAAGGCCAAGAATGGC	480
145	Y N A H N V Y I M T D K A K N G	160
481	ATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGATGGCAGCGTG	528
161	I K V N F K I R H N I E D G S V	176
529	CAGCTGGCCGACCACTACCAGCAGAATACCCCATCGGCGATGGCCCT	576
177	Q L A D H Y Q Q N T P I G D G P	192
577	GTGCTGCTGCCCCGATAACCACTACCTGTCCACCCAGAGCGCCCTGTCC	624
193	V L L P D N H Y L S T Q S A L S	208
625	AAGGACCCCAACGAGAAGCGCGATCACATGATCTACTTCGGCTTCGTG	672
209	K D P N E K R D H M I Y F G F V	224
673	ACCGCCGCCGCCATCACCCACGGCATGGATGAGCTGTACAAGTGA	717
225	T A A A I T H G M D E L Y K *	239

FIG. 23

FIG. 24a




FIG. 24b



FIG. 24c




FIG. 24d




FIG. 24e





FIG. 24f



23/23




FIG. 25